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ABSTRACT 
The Effect of Lipid Composition on Cholesterol-Rich Domain Size in Model 
Membranes 
Angela C. Brown 
Advisor: Steven P. Wrenn 
 
  
 
 
 Lipid rafts are ordered domains of the cell membrane, enriched in 
cholesterol, sphingolipids, and saturated phospholipids, which are hypothesized to 
allow a number of cellular processes to occur.  Because raft coalescence or division 
drives many of these cellular processes, they are dependant not only on the presence 
of lipid rafts, but also on raft size.  This work uses steady-state fluorescent 
techniques, along with a mathematical model, to detect and estimate the size of lipid 
domains in membrane systems modeling natural cell membranes.   
 The fluorescence study was initially performed on a simple two-component 
phospholipid and cholesterol system in order to characterize the behavior of the 
fluorescent probes using a well-established phase diagram and was then extended to 
more biologically-relevant, three-component systems.  Lipid composition and the 
resulting line tension were found to be the most significant factors affecting domain 
size and presence.   
 The kinetics of domain growth and dissipation due to change in composition 
was determined.  The two processes were found to occur on much different time-
scales, with domain growth occurring within several hours and domain dissipation 
occurring within several seconds.  In addition, the rate of cholesterol removal by β-
 xix
cyclodextrin was found to be strongly phase-dependent, extracting cholesterol 
preferentially from the ld phase over the lo phase.       
 The role of lipid rafts in two disease processes, bacterial toxin binding and 
gallstone formation, was also investigated.  A. actinomycetemcomitans produces 
several virulence factors, one of which, a cytotoxin, was found to bind directly to 
membranes containing lipid rafts, while the leukotoxin was found not to bind directly 
to membranes, regardless of the phase.  Estrogen was found to disrupt lipid rafts, 
suggesting that it may act as a pro-nucleating agent in the formation of gallstones.  
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CHAPTER 1: INTRODUCTION 
 
 
 
In recent years, cholesterol has received much attention, mostly due to its role 
in disease processes such as atherosclerosis (1,2) and gallstone pathogenesis (3,4).  
Although the negative aspects of cholesterol receive the majority of popular attention, 
cholesterol is an important biological molecule in eukaryotic organisms, providing 
stability to cell membranes (5) and acting as a precursor to the many hormones that 
are present in these organisms (6,7).  Adding to these important functions is the recent 
discovery of cholesterol-rich lipid rafts in eukaryotic cell membranes and the role 
of rafts in cellular processes.   
Lipid rafts are mobile regions of the cell membrane that are enriched in 
proteins, and are believed to be involved in cellular processes such as lipid and 
protein sorting, cell signaling, and endocytic transport (8-13).  In addition, lipid rafts 
are involved in many disease processes (14-17).  It is apparent that a full 
understanding of the nature of lipid rafts is essential for the study of cellular 
functioning and disease prevention.       
The size of lipid rafts and the factors influencing their size may at first appear 
to be a trivial matter.  However, it has been hypothesized that it is through the 
coalescence or disruption of small, unstable rafts that many of these cellular processes 
occur (16,18,19).  For that reason, raft size is of vital importance in the study of 
cellular functioning. 
Systematic studies of raft size are generally performed in model systems 
composed of one or two types of phospholipids and cholesterol.  These model 
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systems simplify the extremely complex cellular membrane by reducing the number 
of variables to be studied.  Cholesterol-rich domains in model membranes are 
believed to represent the in vitro equivalent of cholesterol-rich rafts in natural 
membranes (in vivo) (20-23).   
A large amount of work has gone into detecting raft size, but a consensus has 
not been reached.  Reported raft sizes vary widely depending on the technique used, 
and the differences between domain size in model membranes and raft size in natural 
membranes is significant.  In natural cell membranes, detected rafts tend to be on the 
order of tens of nanometers (24-27).  Domains on this order have been detected in 
model systems composed of a single phospholipid and cholesterol (28,29); however, 
in more biologically relevant model systems composed of a high-transition 
temperature (Tm) lipid, a low-Tm lipid, and cholesterol, micron-scale domains are 
observed (30-32).  Evidence of smaller, nanoscale domains in these ternary systems 
has been detected, but actual domain sizes have not been measured (33).      
Förster resonance energy transfer (FRET) represents an ideal way to detect 
nanoscale domains in model membranes because of its nanometer-scale sensitivity 
and its low perturbation.  In this work, a systematic FRET study was performed to 
determine the effect of phospholipid chain saturation and length on domain size and 
formation.   
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CHAPTER 2: BACKGROUND 
 
 
 
2.1  Cell Membrane Components 
The structure and composition of biomembranes play important roles in 
cellular functioning by controlling movement of molecules into and out of cells and 
organelles.  The membrane is made of a phospholipid bilayer, which provides two 
important properties: stability and hydrophobicity.  The stability of the membrane, 
which is imparted by hydrophobic and van der Waals forces, allows the membrane to 
maintain its structure in a variety of environments.  The hydrophobicity of the 
membrane interior acts as a barrier to prevent the diffusion of water-soluble solutes 
into the cell (1).   
Eukaryotic cell membranes are composed of simply lipids and proteins; 
however, the variety of lipid and protein types makes the membrane quite complex.   
2.1.1  Lipids 
 There are three types of lipids which make up membranes: 
phosphoglycerides, sphingolipids, and steroids.  All three types of lipids are 
amphiphilic, containing a polar head group and a nonpolar tail.  However, slight 
structural differences between each are responsible for significant differences in their 
roles in the membrane.   
Phosphoglycerides.  Phosphoglycerides contain two fatty acid chains, which 
are attached to a glycerol phosphate by ester linkages.  Also attached to the phosphate 
group is a polar head group such as choline, serine, ethanolamine, glycerol, or 
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inositol.  A diagram of a phosphatidylcholine (PC) molecule, the most abundant 
phospholipid of the plasma membrane (1,2), is shown in Figure 2.1A. 
Phosphoglycerides are named by their fatty acid and head group types and are 
abbreviated with a four letter acronym, in which the first two letters describe the fatty 
acid type and the second two letters describe the head group type.  For example, 1,2-
dimyristoyl-sn-glycero-3-phosphocholine, which contains two myristic acid chains 
and a choline headgroup, is abbreviated DMPC, and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoethanolamine, which contains one palmitic acid chain and one oleic acid 
chain and an ethanolamine headgroup, is abbreviated POPE.     
Sphingolipids.  On first glance, sphingolipids appear to be similar to 
phosphoglycerides due to their two long hydrocarbon chains and polar head group.  
However, sphingolipids are derived from the sphingosine molecule, which is an 
amino alcohol with a long hydrocarbon tail.  The second long hydrocarbon chain is a 
fatty acid connected to the amino group of the sphingosine group.  The sphingolipid 
may contain a polar head group, such as phosphocholine or a sugar, attached to the 
alcohol or, in the case of ceramide, it may contain no head group (1).  The structure of 
sphingomyelin (SM), which is a sphingolipid with a phosphocholine head group, is 
shown in Figure 2.1B.   
Steroids.  The steroids are characterized by a four-ring structure.  The 
structure of cholesterol, the most common sterol in mammalian cells (3), consists of 
four rings with a hydroxyl group, a double bond, and an iso-octyl hydrocarbon side 
chain.  The rings are in the trans conformation, making the molecule extremely 
planar and rigid, with the exception of the hydrocarbon side chain (2).  The hydroxyl 
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group provides the hydrophilic portion to make the molecule amphiphilic so that it is 
able to associate with the membrane (1).  The structure of cholesterol is shown in 
Figure 2.1C.      
Differences Between Sphingolipids and Phosphoglycerides.  Sphingolipids 
and phosphoglycerides share many similar characteristics, most notably, the two long 
hydrocarbon chains and the polar head group.  However, slight differences between 
these two classes of molecules have been found to be responsible for variations in 
their interactions within the membrane.   
While both phosphoglycerides and sphingolipids contain long hydrocarbon 
chains, the length and saturation of the chains is different in each.  The hydrocarbon 
chains of PC tend to be of similar lengths, with one being fully saturated and one 
being unsaturated (1).  Sphingolipids tend to contain fully saturated hydrocarbon 
chains, with one chain being longer than the other (1,2).  Overall, SM chains tend to 
be longer and more fully saturated than PC chains (3).     
 Interaction of Cholesterol with Glycerophospholipids and Sphingolipids.  
Cholesterol has been found to interact more strongly with SM than with PC, a fact 
which is often explained by the differences in the hydrogen-bonding abilities of the 
two molecules.  The amide group of SM provides a hydrogen-bond accepting group, 
in addition to the hydrogen-bond donating group that is present in both SM and PC 
(1).  In addition, the saturation of SM and PC is partially responsible for this 
difference in interaction. Cholesterol interacts more favorably with saturated lipids 
because it is better able to pack within the flexible unsaturated hydrocarbon chains, 
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and therefore interacts preferentially with SM, which is usually fully saturated, over 
PC, which tends to be more unsaturated (1).   
2.1.2  Proteins 
Three types of proteins, integral, lipid-anchored, and peripheral, associate 
with membranes.  Integral membrane proteins, or transmembrane proteins, contain a 
hydrophobic central region, bound by two hydrophilic regions, allowing the protein to 
span the entire membrane.  Lipid-anchored proteins are covalently attached to a lipid 
which is inserted into the membrane.  Finally, peripheral proteins associate with the 
membrane by interactions with integral membrane proteins or with the lipid head 
groups, but are not directly associated with the membrane (4).      
 2.2  Cell Membrane Arrangement 
The arrangement of the phospholipid and protein components appears to have 
significant effect on membrane function.  In recent years, two models have been used 
to describe membrane organization: the fluid mosaic model and the lipid raft model.     
 2.2.1  Fluid Mosaic Model of Membrane Arrangement 
The groundbreaking fluid mosaic model of 1972 was the first to examine 
membrane organization and its role in cellular functioning.  This model proposed that 
the phospholipids are arranged in a bilayer form with proteins randomly distributed 
throughout.  The lipids are hypothesized to be distributed randomly, with some lipids 
interacting with the integral proteins.  In other words, this model proposes that the 
lipid bilayer acts as a solvent for integral proteins (5).   
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2.2.2  Lipid Raft Model of Membrane Arrangement 
The fluid mosaic model was refined by Simons and Ikonen in 1998 and 
presented as the lipid raft model.  This model proposes that lipids are arranged into 
domains based on their chemical properties, which either include or exclude proteins.  
As in the fluid mosaic model, the lipid bilayer is believed to act as a solvent for 
membrane proteins, but in this model, the bilayer is hypothesized to contain more 
short-range order than in the fluid mosaic model.  Because the domains are mobile, 
they are referred to as lipid rafts and are expected to be used by the cell in transport 
and signaling processes (6). 
The lipid raft model is based on the finding that cold non-ionic detergents, 
such as Triton X-100, solubilize cell membrane components differentially.  The non-
solubilized portions (or detergent resistant membranes (DRMs)) tend to be enriched 
in cholesterol, sphingolipids, and certain types of proteins (7,8).  It is believed that 
these DRMs are the raft portion of the membrane.  Rafts have been implicated in 
many cellular processes, particularly those that require movement or transport such as 
biosynthetic transport, endocytic transport, cell signaling, and lipid and protein 
sorting (8-11).   
2.3  Lipid Phase Behavior 
 The complex, amphiphilic structure of lipids is responsible for interesting 
phase behavior, which has significant implications in cell membrane structure and 
function.      
Phospholipids display a main transition temperature (Tm) at which the order of 
the lipid changes significantly.  At temperatures below the Tm, the lipid exists in a 
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highly ordered solid-ordered (so) state.  Above the Tm, both the translational order 
(the lateral diffusion rate) and the conformational order (the order of the phospholipid 
chains) decrease dramatically, to form a liquid state (12).   
2.3.1  Binary Phospholipid Mixtures 
 Solid-liquid phase coexistence has been observed in binary mixtures of two 
different phospholipids.  Each phase diagram is characterized by a phase transition 
temperature at which the membrane moves from a solid to liquid phase at pure 
compositions.  At intermediate compositions, a solid-liquid coexistence region is 
observed (13-15).   
   For example, a phase diagram for DSPC-DPPC (15) is shown in Figure 
2.2A.  When the mol fraction of DSPC is 0%, a Tm of about 40oC is observed, and 
when the mol fraction of DSPC is 100%, a Tm of about 54oC is observed.  At all other 
compositions, a two-phase (solid-liquid) region is present at temperatures between the 
two pure-component Tm.     
2.3.2  Binary Phospholipid-Cholesterol Mixtures 
 The presence of cholesterol in lipid systems complicates lipid phase behavior 
slightly.  In addition to solid-liquid coexistence, liquid-liquid coexistence is observed 
in systems containing one phospholipid and cholesterol.   
The rigid, planar structure of cholesterol significantly increases the 
conformational order of nearby phospholipid chains (16), while decreasing the 
translational mobility only slightly (12).  Thus, the liquid phase that exists at low 
cholesterol compositions is characterized by non-ordered hydrocarbon chains and a 
very high diffusion coefficient, and the liquid phase that exists at high cholesterol 
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compositions is characterized by highly ordered hydrocarbon chains and a high 
(slightly reduced) diffusion coefficient.  Because of the significant differences in 
conformational order, the cholesterol-poor phase is known as the liquid-disordered 
(ld) phase, and the cholesterol-rich phase is known as the liquid-ordered (lo) phase.    
The lo phase is decreased in cross-sectional area and increased in thickness 
compared to the ld phase due to the alignment of hydrocarbon chains.  In addition, it 
has increased mechanical strength and reduced permeability.  It can therefore be said 
that the lo phase is an intermediate phase between the ld and so phases (9).     
An example of a binary phospholipid-cholesterol phase diagram for the 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC)-Cholesterol (Chol) system is 
provided in Figure 2.2B (17).  At low temperatures, the membrane exists completely 
in a so phase, or at higher cholesterol compositions in a mixed so-lo phase.  At 
temperatures above Tm, the membrane exists in a ld state at low cholesterol 
compositions and in a lo state at high cholesterol compositions.  Within a certain 
cholesterol composition range above Tm, the membrane contains lo and ld phase 
coexistence.  At very high temperatures, the two-phase region is abolished, and the 
membrane exists in either a ld phase at low cholesterol compositions or a lo phase at 
high cholesterol compositions.         
2.3.3  Ternary Phospholipid-Cholesterol Mixtures 
 Systems composed of a low-Tm lipid, a high-Tm lipid, and cholesterol have 
likewise been shown to contain regions of liquid coexistence.  In this case, the ld 
phase is enriched in the low-Tm lipid (usually an unsaturated phospholipid or a very 
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short-chained saturated phospholipid) and the lo phase is enriched in the high-Tm lipid 
(usually a fully saturated phospholipid) and cholesterol. 
 A phase diagram for the 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)-
SM-Chol system is shown in Figure 2.2C (18).  In this system, a large region of ld and 
lo coexistence is observed.  Additionally, there is a region of ld-lo-so coexistence.      
2.3.4  Maximum Solubility of Cholesterol in Membranes    
 It has been shown that cholesterol is soluble in PC membranes at 
compositions up to 66% and in PE membranes at compositions up to 51%.  Above 
these compositions, cholesterol precipitates out of the membrane in cholesterol 
monohydrate crystals (19).   
 An umbrella model was proposed to explain this behavior.  According to 
this theory, cholesterol is shielded by the phospholipid head group from unfavorable 
interactions with water.  PC, with its large head group, is able to shield two 
cholesterol molecules per PC molecule, resulting in a cholesterol solubility of 66% 
(2:1).  PE, which has a smaller head group, can only shield one cholesterol molecule 
per PE molecule, resulting in a cholesterol solubility of 50% (1:1) (20).   
2.4  Model Membranes and Biomembranes 
The finding that rafts are enriched in cholesterol, sphingomyelin, and other 
saturated lipids has led to the hypothesis that they are the in vivo equivalent of the lo 
phase in simple lipid mixtures (21-23).  Adding to this evidence is the fact that 
depletion of cellular cholesterol can severely disrupt cellular functioning (24-26).   
The nanometer-scale size of rafts in natural cell membranes precludes direct 
visualization.  Additionally, differentiation of the two phases is difficult because of 
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their similar mechanical and physical properties (6,27).  Another factor which makes 
studies of rafts in vivo difficult is their transitory nature and the wide variety of 
membrane components.  For these reasons, it is often preferable to study simplified 
model membranes, composed of one or two phospholipids and cholesterol in order to 
investigate molecular interactions systematically (28).   
2.5  Domain and Raft Size 
One of the most perplexing questions about lipid rafts is their size, a question 
that has been complicated by significant differences in model and natural membranes.  
Rafts are believed to be on the order of nanometers in natural membranes, while 
micron-scale domains have been observed in model membranes. 
2.5.1  Raft Sizes in Natural Membranes 
Techniques used to measure raft size in natural cell membranes include single 
particle tracking (SPT), optical laser trap, and FRET.  In SPT, a membrane 
component, usually a GPI-anchored protein or ganglioside GM1, is labeled with a 
colloidal gold molecule or a fluorescent molecule, which is tracked using microscopy 
(29).  Optical trapping likewise requires a membrane component to be labeled, in this 
case with a very small bead, which is trapped by a near-infrared laser.  The particle is 
then dragged across the membrane until an obstacle is reached (29).  Finally, FRET 
can be used in natural membranes by fluorescently labeling GPI-anchored proteins 
(30).  (Note: FRET is discussed in detail in Chapter 4)  A summary of raft sizes 
predicted by these methods is shown in Table 2.1.  In general, lipid raft sizes are on 
the order of 10 to 300 nm.   
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Table 2.1.  Lipid Raft Sizes in Natural Membranes 
Technique Reported Size References 
SPT 200 - 330 nm (31-33)  
Laser Trap 26  44 nm (34,35)  
FRET < 70 nm (36)  
     
 16
2.5.2  Domain Sizes in Model Membranes 
In model membranes, a very wide range of domain sizes has been reported 
depending on the technique used.  The more commonly used techniques for 
determining domain size in model membranes include atomic force microscopy 
(AFM), nuclear magnetic resonance (NMR), confocal microscopy, and FRET.  A 
summary of the reported domain sizes obtained through these techniques is provided 
in Table 2.2. 
Interestingly, domain sizes determined by similar methods sometimes produce 
drastically different results.  For example, domains detected by AFM range from tens 
of nanometers to greater than one micron (37-39), and domains detected by NMR 
range from 80 nm to greater than 1 micron (40,41).  Conversely, FRET and 
microscopy predict similar domain sizes between studies, although significantly 
different results when compared to one another.  FRET tends to detect domains on the 
order of tens of nanometers (42-44), while microscopy detects domains of greater 
than one micron (18,45,46). 
2.5.3  Raft Size Versus Domain Size 
The reported differences in domain size between model and natural systems 
may be explained by variations in line tension.  The phospholipids in the lo phase are 
aligned while the phospholipids in the ld phase are not; this can create a hydrophobic 
mismatch where a portion of the hydrophobic phospholipid chains are exposed to 
water.  This situation is highly unfavorable, and is alleviated through domain 
coalescence.  In a model system, composed of one or two types of phospholipids, this 
hydrophobic mismatch can be significant.  In natural systems, however, there exist a 
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wide range of phospholipid types with varying length and saturation, which may be 
able to act as lineactants to alleviate some of this line tension.  This could explain 
why rafts in natural systems tend to be so much smaller than domains in model 
systems.  Figure 2.3 contains a schematic of a system containing line tension and one 
in which the line tension is alleviated by lineactants.   
Agreement has not yet been reached on raft size in natural membranes or 
domain size in model membranes.  One of the major difficulties is due to the fact that 
various compositions and techniques have been used, making any sort of comparison 
difficult.  A systematic study of the factors affecting domain size is clearly needed.  
Because domains in natural membranes are on the order of nanometers, a tool with 
nanometer sensitivity is needed to perform this systematic study.  FRET has the 
required sensitivity and has been shown to be effective in probing nanoscale phase 
separation in model membranes (44,47).     
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Table 2.2.  Domain Sizes in Model Membranes 
Technique Membrane Composition Reported Size References
AFM DOPC-SM-Chol 40-100 nm (37)  
AFM 1,2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC) - 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC)-Chol
33  48 nm (38)  
AFM DLPC - galactosylceramide 
(GalCer) - Chol 
> 1 µm (39)  
NMR DOPC-DPPC-Chol 80  160 nm (40)  
NMR DOPC-DPPC-Chol > 1 µm (41)  
FRET DOPC-SM-Chol > 10 nm (42)  
FRET DMPC-Chol < 20 nm (43)  
FRET 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine 
(POPC)-SM-Chol 
< 20 nm (44)  
Confocal 
Microscopy 
DLPC-DPPC-Chol > 1 µm (45)  
Confocal 
Microscopy 
DOPC-DPPC-Chol 
DOPC-SM-Chol 
POPC-SM-Chol 
> 1 µm (18,46)  
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Figure 2.1.  Lipid Chemical Structure.  (A) Phosphatidylcholine, a 
glycerophospholipid, (B) Sphingomyelin, a sphingolipid, and (C) cholesterol, a sterol. 
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Figure 2.2.  Phase Diagrams for Lipid Systems.   (A) Binary (two phospholipids) 
phase diagram of DPPC and DSPC (17).  (B) Binary (phospholipid and cholesterol) 
phase diagram of DMPC and Cholesterol (18).  (C) Ternary (two phospholipids and 
cholesterol) phase diagram of DOPC, SM, and Cholesterol (19).   
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Figure 2.3.  Line Tension.  Line tension at the boundary of a lo domain can be 
alleviated by lineactants. 
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CHAPTER 3: RESEARCH GOALS 
 
 
 
 The fact that cell membranes are heterogeneous and that this heterogeneity 
plays a major role in cellular functioning is very well accepted.  Likewise, the 
heterogeneity observed in model membranes is believed to be the in vitro equivalent 
of lipid rafts in vivo.  Here, we detect biologically relevant nanometer-scale domains, 
determine the factors that influence their size, and investigate that effect on disease 
processes.   
This work comprises four specific aims.   
Aim 1.  Develop a steady-state fluorescence assay to determine domain size in 
vitro.  This aim will first require the identification of a FRET pair that exhibits 
differential partitioning between the two liquid phases.  In addition, a model which 
relates steady-state FRET measurements to pure cholesterol domain size will be 
modified to describe cholesterol-rich domain size.     
Aim 2.  Determine the effect of phospholipid properties on domain size and 
presence using the steady-state FRET assay.  The effect of both phospholipid chain 
saturation and chain length will be identified, and insight into the factors that most 
influence domain size will be gained.     
Aim 3.  Investigate the kinetic effects governing domain formation.  The 
overall and phase-specific rates of cholesterol removal from the membrane by β-
cyclodextrin (β-CD) will be determined.  In addition, the time-scales of domain 
formation will be studied.   
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Aim 4.  Study the impact of domain size and presence of domains on specific 
disease processes.  Specifically, the binding of Actinobacillus actinomycetemcomitans 
toxin to rafts will be studied, as well as the influence of estrogen on domain size in 
relation to gallstone formation.   
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CHAPTER 4: MATERIALS AND METHODS 
 
 
 
4.1  Chemicals 
Cholesterol, sodium chloride (NaCl), calcium chloride (CaCl2), sodium azide 
(NaN3), and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) were 
purchased from Sigma Chemical Co. (St. Louis, MO).  DMPC, DOPC, DPPC, 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), POPC, and SM were purchased 
from Avanti Lipids (Alabaster, AL) and Lipoid (Newark, NJ).  Dehydroergosterol 
(DHE) was purchased from Sigma Chemical Co., and 1-myristoyl-2-[12-[(5-
dimethylamino-1-naphthalenesulfonyl)amino]dodecanoyl]-sn-glycero-3-
phosphocholine (DAN-PC) was purchased from Avanti Polar Lipids (Alabaster, AL).  
2-(3-diphenylhexatrienyl)propanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine 
(β-DPH-HPC), 1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p 
toluenesulfonate (TMA-DPH)  and N-(5-dimethylaminonaphthalene-1-sulfonyl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DAN-DHPE) were purchased 
from Molecular Probes/Invitrogen (Carlsbad, CA).  All chemicals were used without 
further purification. 
4.1.1  Fluorescent Probes 
DHE is a fluorescent analog of cholesterol which is used in this work because 
it is structurally similar and has been shown to behave very similarly to cholesterol 
within the membrane (1,2).  In this work, DHE is used as a FRET donor.  The 
structure of DHE is shown in Figure 4.1.   
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 Two different fluorophores, 5-(dimethylamino)naphthalene-1-sulfonyl 
(DANSYL) and diphenylhexatriene (DPH), both of which act as FRET acceptors 
with DHE, were used in this work.  Each of these fluorophores can be located on the 
head or chain of a phospholipid molecule.  This work used DAN-DHPE (head-
labeled DANSYL), DAN-PC (tail-labeled DANSYL), TMA-DPH (head-labeled 
DPH), and β-DPH-HPC (tail-labeled DPH).  The structures of DPH and DANSYL 
are shown in Figure 4.1.  
4.1.2   A. actinomycetemcomitans Toxin 
Purified A. actinomycetemcomitans toxin was obtained from the Boesze-
Battaglia laboratory and stored at -20oC until needed.  Once defrosted, the toxin was 
used immediately and not refrozen.   
4.2  Model Membrane Preparation 
 Two different membrane preparation techniques were used in this work.  Both 
techniques involve the addition of lipids dissolved in chloroform, the evaporation of 
the choloroform, and the addition of aqueous buffer to create multi-lamellar vesicles 
(MLVs), and differ only in the order of the evaporation and aqueous buffer addition 
steps.   
 The film deposition technique was used to label native prairie dog bile with 
fluorescent probes.  MLV solutions were created using the rapid solvent exchange 
(RSE) technique, to avoid artifacts that have been observed at high cholesterol 
compositions when using the film deposition technique.     
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4.2.1  Film Deposition 
 Lipid films were created by adding lipids dissolved in chloroform to 
scintillation vials in the required ratios.  The chloroform was evaporated under a 
stream of nitrogen, while the vial was rotated to create an even lipid film.  Any 
residual chloroform was removed by exposing the samples to a vacuum of 4.92 
inches of mercury absolute pressure overnight.  Films were stored at -20oC until they 
were used.   
This technique is effective in making membranes containing less than 40% 
cholesterol.  However, because the evaporated film state is a highly ordered state, it 
has been suggested that the technique may lead to component demixing and cause 
cholesterol crystallization (3).  For this reason, this technique was not used in any 
compositional studies and was only used in the fluorescent labeling of native prairie 
dog bile.     
4.2.2  Rapid Solvent Exchange 
The RSE technique was created in order to combat the problem of demixing 
found in the film deposition technique.  This preparation method avoids the ordered 
film state by transferring the lipid mixtures directly from the organic (chloroform) 
phase to the aqueous (buffer) phase (3).   
 All vesicle solutions in this work were prepared using RSE. The sample 
components were dissolved in chloroform and added to a 20 mL flat bottom vial in 
the necessary amounts.  3 mL of buffer (0.15M NaCl, 5mM CaCl2, 5mM HEPES, 
3mM NaN3, pH of 7.4) at 60oC was added to the vial, and the solution was vortex 
mixed while exposed to a vacuum of 4.92 inches of mercury absolute pressure for one 
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minute.  The solutions were then diluted with additional buffer to the final desired 
lipid concentration. 
4.3  Fluorescence Spectroscopy 
4.3.1  Spectral Shifts  
 Many fluorophores are polar and exhibit a spectral shift that is induced by a 
polarity change in their local environment.  In a polar environment, solvent molecules 
align around the polar fluorophore, causing the excited energy states to decrease in 
energy.  This decrease in energy corresponds to a longer wavelength of light being 
emitted as the electrons relax to the ground state.  This phenomenon is observed in 
the emission wavelength of the fluorophore; a decrease in maximal emission 
wavelength indicates a decrease in local polarity, and an increase in maximal 
emission wavelength indicates an increase in polarity (4).   
 The polarity-dependent spectral shift is particularly useful in determining the 
phase in which the probe resides, due to the polarity difference between the lo and ld 
phases caused by the cholesterol condensation effect.  The lo phase is slightly less 
polar than the ld phase, because of the exclusion of water molecules by the lipid 
ordering effect of cholesterol (5-7).     
4.3.2  FRET 
When the emission spectrum of a donor molecule overlaps with the excitation 
spectrum of an acceptor, the two molecules interact via dipole-dipole interactions, to 
quench the emission intensity of the donor (4).  This is the phenomenon known as 
FRET.   
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The two factors that affect the extent of FRET are the amount of overlap in 
the donor emission spectrum and the acceptor excitation spectrum, and the distance 
between the two probes (r).  The spectral overlap (J) is related to the Förster distance 
(Ro), or the distance at which FRET is 50% efficient:   
( ) 6/14231079.9 −= nQJxR Do κ     (1) 
where κ2 is the dipole orientation factor, QD is the quantum yield of the donor in the 
absence of acceptor, and n is the refractive index of the medium (4).  The rate of 
energy transfer depends on R
o
, r, and the decay rate of the donor (τD): 
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It is apparent from the dependence of FRET on distance to the sixth power, 
that FRET is very strongly distance-dependent.  This technique is particularly well-
suited to detecting distances on the same order as Ro, which is usually in the range of 
20-60 Å (4).  Therefore, this technique is especially effective at detecting nanoscale 
distances and is occasionally referred to as a spectroscopic ruler (8).     
Relative measures of FRET are always used in order to avoid errors due to the 
lack of standardization of intensity measurements (9).  Two such relative measures 
were used in this work, the efficiency of energy transfer (%E) and the ratio of donor 
peak to acceptor peak (R).     
FRET efficiency is calculated from the measured steady-state fluorescence 
intensity of the donor at its maximal emission wavelength in the presence and 
absence of acceptor:   
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where FDA and FD are the donor emission intensities in the presence and absence of 
acceptor, respectively (4).  An increase in FRET will be observed by an increase in 
%E.   
The ratio of donor to acceptor peaks also provides a relative measure of 
FRET: 
A
D
F
FR =      (4) 
where FD is the intensity of the donor at is maximal wavelength and FA is the intensity 
of the acceptor at its maximal wavelength.  An increase in FRET is observed by a 
decrease in R.   
4.4  Steady-State FRET Model 
The relation of FRET to distance in simple systems containing a single donor 
and acceptor pair at a fixed distance is straight-forward and well-established (10).  
However, relation of FRET to distance in membrane systems is more complex, as 
these systems contain multiple donors with a different distribution of acceptors 
surrounding each.  These complexities have been accounted for in a steady-state 
FRET model that predicts the efficiency of energy transfer from a donor to a random 
distribution of acceptor molecules in an infinitely large monolayer (10):   
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where σ is the surface density of acceptors, and S(t) is the energy transfer term, which 
is given by: 
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In this equation, the lower limit of integration, a, represents the sum of the molecular 
radii.  
This theory can be applied to membrane systems containing domains, with 
three assumptions.  It is assumed that donors are distributed randomly within the 
domain, the domains are circular, and domains are coupled between the top and 
bottom leaflets of the bilayer.   
Energy transfer within a bilayer occurs between donors and acceptors in the 
same monolayer as well as between donors and acceptors in opposite monolayers.  
Equation 6 can modified to describe the contributions from both:   
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where S1 represents energy transfer within the same monolayer 
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and S2 represents energy transfer across the bilayer 
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S1 and S2 account for energy transfer due to all acceptor locations.  In both 
cases, the upper limit of integration is given by infinity, and the lower limits of 
integration (LL1 and LL2) vary.  LL1 represents the smallest possible distance 
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between a donor and acceptor in the same leaflet, and LL2 represents the smallest 
possible distance between a donor and acceptor in opposite leaflets.   
In a membrane system containing domains, both probes can be located in the 
same phase or the probes can be located in opposite phases.  If the donor and acceptor 
are located in the same phase, LL1 is given by the sum of the molecular radii, a, and 
LL2 is given by the bilayer thickness, h (3.6 nm) as seen in Figure 4.2A.  This 
contribution to the overall energy transfer is denoted E
same
.  When the donor and 
acceptor are in different phases, both LL1 and LL2 become a function of domain 
radius, n, as seen in Figure 4.2B; this contribution to the overall energy transfer is 
denoted as Ediff.  In the simplest case, the donor is assumed to reside in the center of 
the domain; LL1 is given by the domain radius, n, and LL2 is given by (n2 + h2)1/2.  
However, the donor is actually randomly distributed within the domain.  This can be 
accounted for by assuming the donors reside on a circle concentric to the domain 
perimeter, with a radius of 0.67n, to approximate the average radial position of a 
donor within the domain as seen in Figure 4.2C.  With this assumption, LL1 is given 
by 0.33n, and LL2 is given by [h2 + (0.33n)2]1/2 .     
The overall, predicted energy transfer is an average between E
same
 and Ediff, 
which is weighted by the partitioning of the donor between the l
o
 and ld phases.   
    diffosamedpred EdEdE +=    (10) 
with dd and do being the mole fraction of donor in the ld and lo phases, respectively.  
E
same
, the energy transfer between donor and acceptor in the same phase, is calculated 
using equations 7, 8, and 9 with LL1 equal to a and LL2 equal to h.  The energy 
transfer between donor and acceptor in different phases, Ediff, is calculated with 
equations 7, 8, and 9 using LL1 of 0.33n and LL2 of [h2 + (0.33n)2]1/2.  The mole 
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fractions d
o
 and dd are determined from a phase diagram with the donor, DHE, 
assumed to partition similarly to cholesterol.   
Input parameters to the model include do and dd, which are determined from 
the phase diagram and the unquenched donor lifetime, τo, which was assumed to be 1 
ns (11).  The parameter Ro, was determined for a sample lying outside the two-phase 
region for each particular sterol composition studied.  This value of Ro was assumed 
to be independent of phospholipid composition within the two-phase region so that 
the same value was used for each sample with the same cholesterol composition.  
This assumption enables a single parameter fit, where the fitted parameter is domain 
radius.     
4.4.1  Comparison of FRET Model with Monte Carlo Simulations 
Determination of the accuracy of the FRET model through comparison with 
domains of known size is impossible with current techniques, due to the small size of 
the predicted domains.  Therefore, accuracy was determined by comparison with an 
off-lattice Monte Carlo simulation developed by Towles and Dan (12).  This 
simulation predicts the energy transfer in a system of known domain size with donor 
and acceptors randomly distributed.  Incorporation of the parameters used in the 
steady-state model allows comparison of the predicted efficiency of the model with 
the simulation. 
Results of this comparison for several compositions are shown in Figure 4.3.  
Figure 4.3A shows the results of the model prediction and simulation prediction for a 
sample containing 20% sterol and 30% DPPC with domains of 3.5 nm (corresponding 
to the experimental results in Chapter 7).  Figure 4.3B contains the comparison for a 
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sample containing 20% sterol and 40% DPPC with a domain radius of 6 nm, and 
Figure 4.3C contains the comparison for a sample containing 30% sterol and 30% 
DPPC with a domain radius of 7.5 nm (again corresponding to experimental results 
presented in Chapter 7). 
It is clear that the model and simulation show similar behavior and that the 
agreement varies depending on the composition and size of the membrane.  In 
general, it can be concluded that the model provides a reasonable prediction of 
domain size.      
4.4.2  Model Sensitivity to Domain Size   
The steady-state FRET model is strongly distance-dependent, but is limited to 
detection of domain sizes on the order of the Förster distance.  If domains are too 
large, model resolution is lost and the predicted FRET profiles no longer vary with 
domain size.  An example of this behavior is shown in Figure 4.4.  In this example, 
domains of 10 nm and 100 nm give very similar FRET profiles and cannot be 
resolved with this model.  In other words, domains larger than about 10 times the 
Förster distance cannot be resolved by the model.      
4.4.3  Effect of Domain Size Polydispersity on Model Predictions 
The model as described, assumes that the domains are monodisperse, but can 
be modified to account for domain size polydispersity if a domain distribution is 
assumed, by integrating over the domain size distribution  
∫=
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0
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n
iiiiPDpred dnnEnNE      (11) 
where Ni is the number fraction of domains of radius ni, nmax is the largest 
possible domain that could be obtained if all the cholesterol and l
o
 lipid were packed 
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into a single domain, and Ei(ni) is the energy transfer efficiency expected for domains 
of radius ni. 
In the case of a normal size distribution, equation 11 can be approximated by 
a summation, weighted by a Gaussian probability density function: 
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where µ is the mean domain radius and σ is the standard deviation.  Figure 4.5 
shows the predicted FRET profiles for domain sizes of 3 nm, 6 nm, 9 nm, and 12 nm 
(Figures 4.5A, 4.5B, 4.5C, and 4.5D, respectively) with polydispersities of 0.0 to 0.5, 
where polydispersity is defined as the standard deviation divided by twice the mean 
domain size  
   
µ
σ
2
=PD
      (13). 
In each example, the predicted FRET profiles increase with increasing degrees 
of polydispersity.  Variation of the FRET profile due to polydispersity is most 
apparent for the smaller domains because of the model sensitivity to domain size.  
The effect of polydispersity is unable to be resolved by the model when the domain 
size is large.    
As seen in Figure 4.5, the monodisperse case always predicts the lowest FRET 
profile.  By assuming a normal distribution, smaller domains, which have high FRET 
profiles and larger domains, which have low FRET profiles are included in the FRET 
prediction.  The smaller domains have a greater impact on the predicted FRET, and 
the polydisperse profile therefore always increases in relation to the monodisperse 
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profile.  As a result, the monodisperse case always predicts the lower limit domain 
size.      
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Figure 4.1.  Chemical Structures of Fluorescent Probes. (A) DHE, (B) DANSYL, 
and (C) DPH.     
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Figure 4.2.  Energy Transfer Geometries.  (A) membranes without domains, (B) 
membranes with domains, and (C) a top-view of the domain, where donors are 
assumed to reside on a ring with radius 0.67 times the domain radius, to represent the 
average radial location of the randomly distributed donors.        
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Figure 4.3.  Comparision of FRET Model and Simulations.  Energy transfer 
efficiencies predicted by the steady-state FRET model ( ) and Monte Carlo 
simulation ( ) for samples containing (A) 20% sterol and 30% DPPC, (B) 20% sterol 
and 40% DPPC, and (C) 30% sterol and 30% DPPC.  Note that the maximum on the 
y-axis is 10%, rather than 100%, for clarity.      
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Figure 4.4.  Model Sensitivity to Domain Size.  Domains larger than about 10 times 
the Förster distance cannot be resolved by the model.  
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Figure 4.5.  Model Sensitivity to Polydispersity.  Predicted FRET profiles for 
samples of (A) 3 nm, (B) 6 nm, (C) 9 nm, and (D) 12 nm with polydispersities of 0.0 
to 0.5.     
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CHAPTER 5: STEADY-STATE FLUORESCENCE ASSAY 
 
 
 
5.1  Introduction 
 In order to identify a FRET pair for this work, characterization of several 
FRET acceptors was performed in the well-studied DMPC-Chol system.  Several 
phase diagrams for this system have been published, and they indicate the presence of 
a two-phase region (ld and lo coexistence) at 30oC between cholesterol compositions 
of about 8% and 28% (1,2).  Detection and measurement of domains requires the use 
of a FRET pair that exhibits differential partitioning between these two phases.   
DHE, a fluorescent analog of cholesterol, was used as the donor in all of these 
studies due to the fact that it has been shown to behave similarly to cholesterol (3,4), 
making it less perturbing of a membrane system than many other types of probes.  In 
this work, it was assumed that DHE partitions between the two phases similarly to 
cholesterol, residing preferentially in the lo phase.  In order for the FRET pair to have 
the required differential partitioning, it was necessary to identify an acceptor that 
resides predominately in the ld phase, and is also an efficient FRET acceptor with 
DHE.  
 Two different acceptor fluorophores, DANSYL and DPH, were studied, and 
the point of labeling (phospholipid head or tail) was varied, making a total of four 
acceptors that were studied as potential FRET acceptors with DHE.  The FRET and 
spectral shift behavior of each of these acceptors was analyzed in detail to fully 
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characterize the behavior of each of the probes and to identify the most suitable FRET 
pair for this work.     
5.2  Experimental Overview 
 Two types of experiments were performed in this work: DAN-PC spectral 
shifts and FRET.  Each of these types of experiments was performed with one of four 
acceptors: head-labeled DPH (TMA-DPH), tail-labeled DPH (β-DPH-HPC), tail-
labeled DANSYL (DAN-PC), or head-labeled DANSYL (DAN-DHPE).     
5.2.1  Sample Preparation 
 Spectral shift samples contained lipids and one of the acceptors; FRET 
samples contained lipids, DHE (donor), and one of the acceptors.  All samples were 
prepared using the RSE technique and were used as MLVs, without further extrusion 
or sonication.   
 All spectral shift samples (Sample Set 5A) contained cholesterol at 
compositions ranging from 0 to 60 mol% and DMPC.  Each sample was labeled with 
DAN-PC, DAN-DHPE, DPH-HPC, or TMA-DPH at an ALR of 0.03.  An additional 
spectral shift sample was created to contain 0 to 50% cholesterol, DAN-PC at an 
ALR of 0.18, and DMPC.  Spectral shift sample compositions are shown in Table 5.1.      
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Table 5.1.  Binary Spectral Shift Sample Compositions 
Sample ID Acceptor ALR % Chol
5A1 DAN-PC 0.03 0  60%
5A2 DAN-DHPE 0.03 0  60%
5A3 β-DPH-HPC 0.03 0  60%
5A4 TMA-DPH 0.03 0  40%
5A5 DAN-PC 0.18 0  50%
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 FRET samples were created in one of two ways.  In order to look at how 
FRET varies due to the phase behavior of the system, samples were created at a fixed 
acceptor-to-lipid ratio (ALR) with varying cholesterol compositions (Sample Set 5B).  
Each of these samples contained 5% DHE, acceptor (either DAN-PC or β-DPH-
HPC), 0-60% cholesterol, and DMPC.  Samples containing DAN-PC were labeled 
with an ALR of 0.03 and those containing β-DPH-HPC were labeled with an ALR of 
0.005.  In the second set of FRET samples, cholesterol composition was held constant 
while ALR was varied (Sample Set 5C).  These samples contained 5% DHE, 40% 
cholesterol, acceptor (DAN-PC, DAN-DHPE, β-DPH-HPC, or TMA-DPH) at an 
ALR of 0.00 to 0.15, and DMPC.  A final set of DAN-PC/DHE FRET samples 
(Sample Set 5D) was created with 5% DHE, DAN-PC at an ALR of 0.18, 0  60% 
cholesterol, and DMPC.  FRET sample compositions are shown in Table 5.2.   
 51
    
 
 
Table 5.2.  Binary FRET Sample Compositions 
Sample ID Acceptor ALR % DHE % Chol 
5B1 DAN-PC 0.03 5% 0  60% 
5B2 β-DPH-HPC 0.005 5% 0  60% 
5C1 DAN-PC 0.00  0.15 5% 40% 
5C2 DAN-DHPE 0.00  0.15 5% 40% 
5C3 β-DPH-HPC 0.00  0.15 5% 40% 
5C4 TMA-DPH 0.00  0.15 5% 40% 
5D3 DAN-PC 0.18 5% 0  60% 
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5.2.2.  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
Spectral shift samples containing DAN-PC or DAN-DHPE were excited at 
350 nm and the emission spectra were recorded from 400 to 600 nm.  Spectral shift 
samples containing β-DPH-HPC or TMA-DPH were excited at 310 nm and the 
emission spectra were recorded from 340 to 500 nm.  All FRET samples were excited 
at 300 nm and the emission spectra were recorded from 325 to 550 nm.  All emission 
scans were conducted at 30oC unless otherwise specified.  The emission profiles were 
smoothed using a Savitsky and Golay protocol (5).     
5.3  Results 
5.3.1  Partitioning of Dansylated Lipids into Liquid Domains 
 Figure 5.1 shows the emission maximal wavelength as a function of 
cholesterol composition in vesicles labeled with the four different acceptor molecules.  
The two DANSYL probes show a marked change in emission wavelength at high 
cholesterol compositions, while the two DPH probes show a constant emission 
wavelength for all cholesterol compositions.  This confirms that the changes that are 
observed as a function of cholesterol in the DANSYL-containing membranes is a 
polarity effect, as DANSYL is polar and DPH is not.   
 DAN-PC has a maximum emission wavelength of about 515 nm at cholesterol 
compositions below about 25%.  Above this cholesterol composition, a steep blue 
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shift is observed, indicating that the local environment of DAN-PC is less polar at 
these high cholesterol compositions than it is at the lower cholesterol compositions.  
DAN-DHPE shows similar behavior, with an emission maximum of about 500 nm 
that is constant for cholesterol compositions below 25%.  However, DAN-DHPE 
undergoes a red shift at cholesterol compositions greater than 25%, suggesting an 
increase in polarity of the local environment.   
 The temperature effect of the DAN-PC blue shift is examined in Figure 5.2.  
This figure shows the DAN-PC emission maximum wavelengths as a function of 
cholesterol at 30oC, 40oC, 50oC, and 60oC.  At each temperature, a blue shift is 
observed in the DAN-PC emission maximum, but the cholesterol composition at 
which the blue shift is initiated varies depending on the temperature.  The points of 
discontinuity, or the cholesterol compositions at which the blue shifts are initiated, 
were determined using a semi-continuous piecewise fit, and are mapped on a phase 
diagram for the DMPC-Chol system (1) in Figure 5.3.       
 These points of discontinuity were found to occur at cholesterol compositions 
of 21%, 30%, 36%, and 42% for samples at 30oC, 40oC, 50oC, and 60oC, respectively.  
On the reported phase diagram for this system, these points of discontinuity appear to 
align with the point at which the membrane becomes entirely lo at each temperature.  
DAN-PC is insensitive to any changes in polarity at cholesterol compositions lower 
than this composition, observed by the constant emission maximum.  DAN-PC is not 
sensitive to any cholesterol-dependent polarity changes until the cholesterol 
composition at which the membrane becomes entirely lo.  This phenomenon indicates 
that DAN-PC resides predominately in the ld phase when both phases are present.  At 
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higher cholesterol compositions, the membrane becomes entirely lo and DAN-PC is 
forced into the lo phase, evidenced by the initiation of the blue shift at this 
composition.      
5.3.2  Detection of Liquid-Liquid Coexistence by FRET 
 Figure 5.4 shows FRET in membranes labeled with DHE and DAN-PC at 
30oC and 60oC.  At 30oC, a minimum of FRET efficiency is observed at cholesterol 
compositions at which two liquid phases coexist (intermediate cholesterol 
compositions).  Maximal FRET efficiencies are observed at compositions at which 
the membrane contains only one phase (very low and high cholesterol compositions).  
This behavior suggests that the two probes partition differentially between the two 
liquid phases, with the increased distance between the probes resulting in the 
observed decrease in energy transfer as the two phases form.   
 At 60oC, the FRET efficiency remains fairly constant for all cholesterol 
compositions.  This indicates that the probes do not undergo any separation, a fact 
which agrees with the phase diagram for the system.  It can therefore be concluded 
that DAN-PC and DHE partition differentially between the lo and ld phases.     
 A second FRET pair, β-DPH-HPC/DHE was studied and the FRET behavior 
is shown in Figure 5.5.  This FRET pair shows constant FRET behavior at 30oC, even 
as two liquid phases form, indicating that no probe separation occurs, which prohibits 
its use in this study.       
5.3.3  Effect of High Probe Concentration on DMPC-Cholesterol Membranes 
 One weakness of the DAN-PC/DHE FRET pair is the high probe 
concentration that is required to minimize the signal-to-noise ratio.  High amounts of 
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DHE (5% in this work) are required because of its low quantum yield.  This 
necessitates a high concentration of the FRET acceptor (up to an ALR of 0.12) as 
well.  Although these probe compositions are high, we have found that DHE is not 
self-quenching at compositions up to 5%, and DAN-PC is not self-quenching at 
compositions up to 12%.   
 A major concern, however, is perturbation due to the high probe 
concentrations.  The DAN-PC spectral shift and DAN-PC/DHE FRET experiments 
were repeated using a very high DAN-PC ALR (0.18) to determine how probe effects 
could disrupt the system.  Figure 5.7 shows the DAN-PC (ALR = 0.18) spectral shifts 
at 30oC, 40oC, 50oC, and 60oC.  Qualitatively, the results appear similar to those in 
Figure 5.2 (DAN-PC spectral shifts with ALR = 0.03); however, the points of 
discontinuity are shifted significantly towards lower cholesterol compositions, and 
they no longer map entry of the membrane into the entirely lo phase. 
 Likewise, the DAN-PC/DHE FRET behavior at an ALR of 0.18 is 
qualitatively similar to the FRET behavior at a lower ALR, as seen in Figure 5.8.  A 
minimum energy transfer value is observed, as in the lower ALR case, but the 
minimum is shifted to higher cholesterol compositions, and the FRET behavior no 
longer reflects binary phase behavior.   
 In fact, comparison of Figure 5.8 with a ternary phase diagram (DOPC-DPPC-
Chol) (6) provides additional insight into the effect of high probe concentrations.  
Distinct discontinuities in the FRET behavior of Figure 5.8 occur at cholesterol 
compositions of 15% and 45%.  If one assumes that DAN-PC behaves similarly to 
DOPC (DAN-PC containing a bulky fluorescently-labeled tail and DOPC containing 
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two unsaturated chains) and that DMPC behaves similarly to DPPC (both containing 
medium-length, fully saturated chains), these cholesterol compositions align with the 
lower and upper edges of the two-phase region in the DOPC-DPPC-Chol phase 
diagram, as shown in Figure 5.9.  This behavior suggests that at this high DAN-PC 
ALR, the system is no longer a binary (DMPC-Chol) system, but rather a ternary 
(DAN-PC-DMPC-Chol) system.   
5.4  Discussion 
5.4.1  DPH/DHE as a FRET Pair 
The two DPH probes used in this work show promise as FRET acceptors to be 
used with DHE, because of their significant spectral overlap with DHE, which results 
in a strong FRET signal and allows low ALRs to be used.  However, DPH FRET 
behavior indicates that there is little, if any, differential partitioning of DPH and DHE 
between the two liquid phases.  This results in DPH being an unacceptable FRET 
acceptor to be used with DHE for the purposes of detecting and measuring domains.   
5.4.2  DANSYL/DHE as a FRET Pair 
DAN-PC and DHE, on the other hand, display the required differential 
partitioning that is required for this work.  In addition, the spectral shift behavior of 
DAN-PC is useful in the determination of the lo phase transition.  The high probe 
concentration that is required, particularly in the FRET studies, is problematic 
however.   
The presence of a third component, particularly one that contains a bulky 
fluorophore, is undesirable in studies in binary systems.  It was found that in a ternary 
system, DAN-PC acts as similarly to the unsaturated component, and would be a 
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more accurate probe of phase behavior in ternary systems than in binary systems.  For 
this reason, all domain size measurements will be obtained only in ternary systems to 
minimize membrane perturbation.   
5.5  Conclusions 
DAN-PC and DHE exhibit the desirable differential partitioning, with DHE 
residing predominately in the lo phase and DAN-PC residing almost exclusively in the 
ld phase.  Because of the high probe composition that is required with this FRET pair, 
determination of domain sizes will be done only in ternary systems.  This type of 
system is much less likely to be perturbed by the presence of DAN-PC than a system 
containing only high-Tm (saturated) phospholipids.   
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Figure 5.1.  Acceptor Spectral Shifts.  Emission maximal wavelength in DMPC-
Chol membranes for DAN-PC ( ), DAN-DHPE ( ), β-DPH-HPC ( ), and TMA-
DPH ( ).   
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Figure 5.2.  DAN-PC Spectral Shifts in DMPC-Chol Membranes.  The emission 
maximal wavelength of DAN-PC in DMPC-Chol membranes at 30oC ( ), 40oC ( ), 
50οC ( ), and 60oC ( ) undergoes a steep temperature-dependent blue shift at a 
particular cholesterol composition.   
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Figure 5.3.  DAN-PC Spectral Shift Discontinuities.  The points of discontinuity in 
DAN-PC spectral shift experiments in DMPC-Chol membranes are plotted on aphase 
diagram for DMPC-Chol (1).   
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Figure 5.4.  DHE and DAN-PC FRET in DMPC-Chol Membranes.  FRET 
between DHE and DAN-PC in DMPC-Chol membranes displays a minimum at 30oC 
( ), but is constant at 60oC ( ). 
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Figure 5.5.  DHE and β-DPH-HPC FRET in DMPC-Chol Membranes at 30oC. 
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Figure 5.6.  FRET Profiles of Four FRET Pairs.  DHE displays very different 
FRET profiles with DAN-PC ( ), DAN-DHPE ( ), β-DPH-HPC ( ), and TMA-DPH 
( ) in DMPC membranes containing 45% sterol at 30oC.     
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Figure 5.7.  DAN-PC Spectral Shifts with ALR = 0.18.  The emission maximal 
wavelength of DAN-PC (ALR = 0.18) in DMPC-Chol membranes at 30oC ( ), 40oC 
( ), 50οC ( ), and 60oC ( ) is shifted to lower cholesterol compositions compared to 
the ALR = 0.03 case (Figure 5.2).   
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Figure 5.8.  DHE and DAN-PC FRET with ALR = 0.18.  FRET between DHE and 
DAN-PC (ALR = 0.18) in DMPC-Chol membranes at 30oC displays a minimum that 
is shifted to higher cholesterol compositions compared to the ALR = 0.03 case 
(Figure 5.4).  
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Figure 5.9.  DAN-PC (ALR = 0.18) Spectral Shift Discontinuities.  The points of 
discontinuity in the FRET profile of DMPC-Chol vesicles labeled with DAN-PC at an 
ALR of 0.18 can be superimposed on a phase diagram for the ternary DOPC-DPPC-
Chol system (6).  DAN-PC at this high ALR was assumed to act similarly to DOPC 
and DMPC was assumed to act similarly to DPPC.     
 
 
 
 
 
•  
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CHAPTER 6: DETECTION OF lo BOUNDARY USING DAN-PC SPECTRAL 
SHIFTS 
 
 
 
6.1  Introduction 
 We observed previously, that DAN-PC is excluded almost entirely from the lo 
phase as long as some ld phase is present in the system.  DAN-PC undergoes a 
marked blue shift at the composition at which the membrane becomes entirely lo, and 
this blue shift can therefore be used to detect the lo transition.  Here, we apply the 
DAN-PC spectral shift assay to five ternary systems, each containing a low-Tm 
phospholipid, a high-Tm phospholipid, and cholesterol.   
In three of the systems, the high-Tm phospholipid was DPPC, a phospholipid 
with two fully saturated 16-carbon chains (16:0).  In these two systems, the low-Tm 
component was DOPC, a di-unsaturated phospholipid with 18-carbon chains (18:1); 
POPC, an asymmetrical phospholipid with one unsaturated 18-carbon chain and one 
saturated 16-carbon chain (18:1-16:0); or DLPC, a fully saturated phospholipid with 
two 12-carbon chains (12:0).   
  The high Tm-phospholipid was likewise varied.  DPPC was replaced with 
DSPC, a phospholipid with fully saturated 18-carbon chains (18:0).  The first of these 
DSPC systems contained DOPC and the second contained POPC.   
Use of these five ternary systems allowed for comparison of phospholipid 
chain saturation and chain length on the presence and composition of the lo transition.  
Additionally, the effect on temperature on the lo transition was studied in the two 
DSPC ternary systems.     
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The DOPC-DPPC-Chol and POPC-DPPC-Chol systems have been studied in 
detail by other groups; it has been established that the DOPC-DPPC-Chol system 
contains a two-phase region but the POPC-DPPC-Chol system does not (1-3).  The 
DLPC-DPPC-Chol system has also been shown to contain regions of phase 
coexistence although the phase behavior is less well-defined than in the other two 
DPPC systems (4).  The DSPC systems have received less attention.  Evidence of 
two-phase coexistence has been detected in the DOPC-DSPC-Chol system (3,5) and 
complex, but unspecified phase behavior has been detected in the POPC-DSPC-Chol 
system (6).  No evidence of any direct ld-to-lo phase transition has been detected in 
any of these systems.       
6.2  Experimental Overview 
The DAN-PC spectral shifts as a function of cholesterol composition were 
determined in five different ternary systems: DOPC-DPPC-Chol, POPC-DPPC-Chol, 
DLPC-DPPC-Chol, DOPC-DSPC-Chol, and POPC-DSPC-Chol.   
6.2.1  Sample Preparation 
 Each sample type contained a low-Tm phospholipid (DOPC, POPC, or 
DLPC), a high-Tm phospholipid (either DSPC or DPPC), and cholesterol.  Samples 
were labeled with DAN-PC at an ALR of 0.03.  All samples were prepared using the 
RSE technique, and MLVs were used without further treatment.    
 In the DOPC-DPPC-Chol, POPC-DPPC-Chol, and DLPC-DPPC-Chol 
systems, samples were created along lines of constant DPPC composition with 
cholesterol compositions ranging from 0 to 60 in 5% increments.  The DOPC-DPPC-
Chol samples (Sample Set 6A) contained 0%, 20%, 30%, 40%, 60%, or 80% DPPC; 
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the POPC-DPPC-Chol samples (Sample Set 6B) contained 0%, 20%, 40%, 60%, or 
80% DPPC; and the DLPC-DPPC-Chol samples (Sample Set 6C) contained 0%, 
20%, 40%, 60%, or 80% DPPC.  Each sample was labeled with DAN-C at an ALR of 
0.03 as a fraction of the unsaturated lipid component (DOPC or POPC).  
Samples in the DOPC-DSPC-Chol system were created along lines of either 
constant DSPC composition (Sample Set 6D) or constant DOPC composition 
(Sample Set 6E).  Sample Set 6D contained 0%, 5%, 10%, 20%, 30%, 40%, 50%, 
60%, or 80% DSPC; and Sample Set 6E contained 5%, 10%, 20%, 30%, 40%, 50%, 
60%, or 80% DOPC.  Likewise, spectral shift samples in the POPC-DSPC-Chol 
system were created along lines of either constant DSPC composition (Sample Set 
6F) or constant POPC composition (Sample Set 6G).  Sample Set 6F contained 0%, 
5%, 10%, 20%, 30%, 40%, 50%, 60%, or 80% DSPC; and Sample Set  6G contained 
5%, 10%, 20%, 30%, 40%, 50%, 60%, or 80% POPC.  In each sample set, cholesterol 
was varied in 5% increments, and DAN-PC was used at an acceptor-to-lipid ratio 
(ALR) of 0.03, as a fraction of the DOPC or POPC.   The spectral shift sample 
compositions are shown in Table 6.1 and Figure 6.1.   
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Table 6.1.  Ternary Spectral Shift Sample Compositions 
Sample ID Low-Tm lipid High-Tm lipid % DPPC % Chol
6A-1 DOPC DPPC 0% 0  60%
6A-2 DOPC DPPC 20% 0  60%
6A-3 DOPC DPPC 30% 0  60%
6A-4 DOPC DPPC 40% 0  55%
6A-5 DOPC DPPC 60% 0  35%
6A-6 DOPC DPPC 80% 0  15%
Sample ID Low-Tm lipid High-Tm lipid % DPPC % Chol
6B-1 POPC DPPC 0% 0  60%
6B-2 POPC DPPC 20% 0  60%
6B-3 POPC DPPC 40% 0  55%
6B-4 POPC DPPC 60% 0  35%
6B-5 POPC DPPC 80% 0  15%
Sample ID Low-Tm lipid High-Tm lipid % DPPC % Chol
6C-1 DLPC DPPC 0% 0  60%
6C-2 DLPC DPPC 20% 0  60%
6C-3 DLPC DPPC 40% 0  55%
6C-4 DLPC DPPC 60% 0  35%
6C-5 DLPC DPPC 80% 0  15%
Sample ID Low-Tm lipid High-Tm lipid % DSPC % Chol
6D-1 DOPC DSPC 0% 0  60%
6D-2 DOPC DSPC 5% 0  60%
6D-3 DOPC DSPC 10% 0  60%
6D-4 DOPC DSPC 20% 0  60%
6D-5 DOPC DSPC 30% 0  60%
6D-6 DOPC DSPC 40% 0  55%
6D-7 DOPC DSPC 50% 0  45%
6D-8 DOPC DSPC 60% 0  35%
6D-9 DOPC DSPC 80% 0  15%
Sample ID Low-Tm lipid High-Tm lipid % DOPC % Chol
6E-1 DOPC DSPC 5 0  60%
6E-2 DOPC DSPC 10 0  60%
6E-3 DOPC DSPC 20 0  60%
6E-4 DOPC DSPC 30 0  60%
6E-5 DOPC DSPC 40 0  55%
6E-6 DOPC DSPC 50 0  45%
6E-7 DOPC DSPC 60 0  35%
6E-8 DOPC DSPC 80 0  15%
Sample ID Low-Tm lipid High-Tm lipid % DSPC % Chol
6F-1 POPC DSPC 0% 0  60%
6F-2 POPC DSPC 5% 0  60%
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Table 6.1 (continued) 
6F-3 POPC DSPC 10% 0  60%
6F-4 POPC DSPC 20% 0  60%
6F-5 POPC DSPC 30% 0  60%
6F-6 POPC DSPC 40% 0  55%
6F-7 POPC DSPC 50% 0  45%
6F-8 POPC DSPC 60% 0  35%
6F-9 POPC DSPC 80% 0  15%
Sample ID Low-Tm lipid High-Tm lipid % POPC % Chol
6G-1 POPC DSPC 5% 0  60%
6G-2 POPC DSPC 10% 0  60%
6G-3 POPC DSPC 20% 0  60%
6G-4 POPC DSPC 30% 0  60%
6G-5 POPC DSPC 40% 0  55%
6G-6 POPC DSPC 50% 0  35%
6G-7 POPC DSPC 60% 0  25%
6G-8 POPC DSPC 80% 0  15%
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6.2.2  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
Spectral shift samples were excited at 350 nm and the emission spectra were 
recorded from 400 to 600 nm.  All emission scans were conducted at 30oC unless 
otherwise specified.  The emission profiles were smoothed using a Savitsky and 
Golay protocol (7).     
6.3  Results 
6.3.1  DOPC-DPPC-Chol, POPC-DPPC-Chol, and DLPC-DPPC-Chol Systems 
 Figure 6.2 shows the DAN-PC spectral shift in DOPC-DPPC-Chol 
membranes for several DPPC compositions.  The samples containing 0% DPPC (that 
is, the binary DOPC-Chol edge of the phase diagram) display a constant emission 
maximum for all cholesterol compositions, indicating that the membrane does not 
become entirely lo at any cholesterol composition along this binary edge.  The 
remaining samples display a blue shift at a particular cholesterol composition.  The 
initiation of the blue shift is interpreted as the cholesterol composition above which 
the membrane is completely lo.     
The DAN-PC emission maximum in POPC-DPPC-Chol membranes is shown 
in Figure 6.3.  Each DPPC composition line displays a constant emission maximal 
wavelength until a particular cholesterol composition at which a blue shift is 
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observed.  Likewise, the DAN-PC emission maxima in DLPC-DPPC-Chol 
membranes, shown in Figure 6.4 display a cholesterol-dependent blue shift.    
 In each of these systems, the cholesterol compositions at which the blue shift 
occurs, or the point of discontinuity in Figures 6.2, 6.3, and 6.4, were determined 
using a piecewise continuous fit.  These points of discontinuity, which are interpreted 
as the boundary at which the membrane becomes entirely lo, are shown on phase 
maps for these ternary systems in Figure 6.5.  All three of these ternary systems 
appear to contain a lo transition.  At cholesterol compositions above this transition, 
the membrane is entirely lo.  Below the transition, the membrane is either entirely ld 
or contains ld-lo coexistence.   
Several differences in the transition between the three systems can be 
observed.  Most notable is the cholesterol compositions at which the transition occurs.  
This transition occurs at cholesterol compositions which are greatest in the DOPC-
DPPC-Chol system, and least in the DLPC-DPPC-Chol system.  This behavior 
suggests that DOPC-DPPC-Chol membranes are less prone to order than POPC-
DPPC-Chol membranes which are less prone to order than DLPC-DPPC-Chol 
membranes.   
In addition, the lo transition in the POPC-DPPC-Chol system and in the 
DLPC-DPPC-Cho system extends the entire way across the phase map; in the DOPC-
DPPC-Chol system, the transition does not extend to the binary DOPC-Chol edge of 
the phase map.  This indicates that both POPC and DLPC are able to form an ordered 
phase if enough cholesterol is present, but DOPC does not form an ordered phase at 
any cholesterol composition.             
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6.3.2  DOPC-DSPC-Chol and POPC-DSPC-Chol Systems 
 In the binary (DMPC-Chol) spectral shift experiments, cholesterol was varied 
in 5% increments, and DMPC therefore varied likewise.  When the system is instead 
ternary, variation of cholesterol allows for one of the two phospholipid components to 
be held constant while the other varies, or variation of both phospholipids at a 
constant ratio.  In the previously described DOPC-DPPC-Chol and POPC-DPPC-
Chol spectral shift experiments, samples were created along lines of constant DPPC 
composition, so that DOPC and Chol composition varied. To ensure that the lo 
transitions that are observed are not simply artifacts of this arbitrary decision, and are 
instead true lo transitions, the phospholipid component held constant was varied in 
this work.  That is, one set of samples was created along lines of constant DSPC 
composition and another set of samples was created along lines of constant DOPC or 
POPC composition.   
The DAN-PC emission maximum as a function of cholesterol composition in 
DOPC-DSPC-Chol membranes at 30oC is shown in Figure 6.6.  Figure 6.6A shows 
the shifts in samples along lines of constant DSPC compositions (Sample Set 6D) and 
Figure 6.6B shows the shifts in samples along lines of constant DOPC compositions 
(Sample Set 6E).  Steep blue shifts are observed in both figures, suggesting the 
existence of a lo transition as was observed in the DOPC-DPPC-Chol system.   
Figure 6.7 shows the DAN-PC spectral shift in POPC-DSPC-Chol membranes 
at 30oC, with Figure 6.7A showing the results in samples with constant DSPC 
compositions (Sample Set 6F), and Figure 6.7B showing the results in samples with 
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constant DOPC compositions (Sample Set 6G).  Points of discontinuity are observed 
in Figure 6.7, regardless of the component held constant.   
The points of discontinuity, as determined from a semi-continuous piecewise 
fit, from Figures 6.6 and 6.7 are shown on a phase map for each ternary system in 
Figure 6.8.  In each system, a distinct boundary is observed regardless of which 
phospholipid component is held constant.  We interpret this boundary as the point at 
which the membrane becomes entirely lo.  At compositions below the boundary, the 
membrane is either ld or in a two-phase (ld and lo) region, and above it, the membrane 
is entirely lo.   
This lo boundary is not unique to membranes at 30oC.  The DAN-PC spectral 
shift results in DOPC-DSPC-Chol membranes at 60oC are shown in Figure 6.9, with 
Figure 6.9A containing results in membranes with constant DSPC and Figure 6.9B 
containing results in membranes with constant DOPC.  DAN-PC spectral shift results 
in POPC-DSPC-Chol membranes containing constant DSPC or constant POPC at 
60oC are shown in Figures 6.10A and 6.10B, respectively.   
The points of discontinuity from Figure 6.9 and 6.10 are shown on phase 
maps for the two ternary systems in Figure 6.11.  As in the membranes at 30oC, a lo 
boundary is observed, regardless of the phospholipid component held constant.  In 
both the DOPC-DSPC-Chol and the POPC-DSPC-Chol systems, the transition occurs 
at higher cholesterol compositions at 60oC than at 30oC.  Also, the transition occurs at 
higher cholesterol compositions in the DOPC-DSPC-Chol system as compared to the 
POPC-DSPC-Chol system.   
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6.4  Discussion 
The DAN-PC spectral shift provides new information about all of the ternary 
systems studied here.  Other analytical techniques have detected regions of two-phase 
coexistence in ternary systems, but detection of any direct ld-to-lo transitions has not 
been possible.  The DAN-PC spectral shift detects this transition readily, and provides 
additional useful information about the phase behavior of these ternary systems. 
A lo transition was observed in each of the five ternary systems studied in this 
work, indicating that all of the systems contain both ld and lo phases.; the presence of 
a two-phase region is not required for a lo transition to be present.   
6.4.1.  Effect of Chain Saturation of the Low-Tm Lipid on the lo Transition  
DPPC-Containing Systems.  The lo transition was observed to occur at very 
high cholesterol compositions in the DOPC-DPPC-Chol system, at intermediate 
cholesterol compositions in the POPC-DPPC-Chol system, and at very low 
cholesterol compositions in the DLPC-DPPC-Chol system.  In other words, systems 
with a more saturated low-Tm (such as DLPC) component have a lo transition at lower 
cholesterol compositions than systems with a less saturated low-Tm component (such 
as DOPC).    
In the DOPC-DPPC-Chol system, the DAN-PC spectral shift behavior along 
the binary DOPC-Chol edge indicated that a lo phase does not form at any cholesterol 
composition.  However, in the POPC-DPPC-Chol system, along the binary POPC-
Chol edge, a lo phase forms at 41% cholesterol and along the binary DLPC-Chol edge 
the lo phase forms at 35% cholesterol.  The change in saturation of just one of the 
hydrocarbon chains has a significant effect on the ordering behavior of these systems. 
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DSPC-Containing Systems.  In the two DSPC-containing systems, the lo 
transition was again observed to depend upon the saturation of the low-Tm 
component.  That is, systems with a more saturated the low-Tm lipid have a lo 
transition which occurs at lower the cholesterol compositions than systems with a less 
saturated high-Tm lipid.  This behavior is exactly the same as that observed in DPPC-
containing systems.   
Overall Effect of Chain Saturation.  In general, it was observed that the 
cholesterol composition of the lo transition is indirectly related to the saturation of the 
low-Tm lipid.  When the low-Tm lipid is highly saturated, the cholesterol composition 
at which the lo transition occurs is lower than when the low-Tm lipid is less saturated.  
This effect is due to the propensity of each lipid to order.  Fully saturated lipids are 
readily ordered by cholesterol compared to unsaturated lipids; therefore, less 
cholesterol is required to form the ordered phase.   
6.4.2  Effect of Chain Length of the High-Tm Lipid on the lo Transition 
In DSPC systems, the lo transition occurred at lower cholesterol compositions 
compared to the DPPC systems.  In all cases, the cholesterol composition at which the 
lo transition occurs is lower in systems with high-Tm lipids containing longer chains 
(i.e. DSPC)  than in those containing lipids with shorter chains (i.e. DPPC).  As with 
the saturation effect of the low-Tm lipid, the effect of chain length is directly due to 
the likelihood of ordering of the lipids.  Longer-chained lipids, such as DSPC, are 
more easily ordered than shorter-chained lipids, such as DPPC, and therefore less 
cholesterol is required to order DSPC than DPPC.     
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6.4.3  Effect of Temperature on the lo Transition 
Heating of the systems to 60oC causes the lo transition to shift to higher 
cholesterol compositions when compared to systems at 30oC.  Heating increases the 
disorder in the system, and more cholesterol is required to order the system than when 
the system is at a lower temperature.  Heating to 60oC does not eliminate the lo 
transition however.     
6.4.4  Summary of Factors Affecting the lo Transition  
The DAN-PC spectral shift results that are observed in this work agree with 
the ability of each of the phospholipids to order, and is related to the Tm of each 
phospholipid and the temperature of the entire system.  Lipids with a high Tm are 
more likely to be ordered than those with a low Tm (more heat is required to disturb 
the highly-ordered so phase).  While the Tm of a lipid describes the solid-to-liquid 
transition of a lipid and not the ld-to-lo transition that is studied in this work, it appears 
to be related, through the ability of the lipid to be ordered, to the ld-to-lo transition.  In 
other words, there appears to be a Tm at which the lipid undergoes an ld-to-lo 
transition which is directly related to the Tm of the lipid.  Just as the Tm of a lipid 
mixture varies, depending on the composition, Tm appears to be directly dependent 
on the lipid composition of the system. 
Figure 6.12 shows a summary of the lo transition points (mol% cholesterol) as 
a function of the weighted average Tm of each membrane composition (weighted by 
the molar amount of each lipid).  It is clear that in each ternary lipid system, there is 
an indirect linear relation between the amount of cholesterol required to order the 
membrane and the average (solid-liquid) Tm of the system.            
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6.5  Conclusions 
The lo transition was found to occur in all five ternary systems, regardless of 
the phospholipid chain length or chain saturation.  The amount of cholesterol required 
for the formation of the lo phase depends on the propensity of the combination of 
phospholipids to order, which is related to the solid-liquid Tm.  Phospholipids with a 
higher Tm, require less cholesterol to become lo.  It is proposed that there exists a Tm 
which is related to Tm and describes the transition from ld to lo.   
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Figure 6.1.  Ternary Spectral Shift Sample Compositions.  (A) DOPC-DPPC-Chol, 
(B) POPC-DPPC-Chol, (C) DLPC-DPPC-Chol, (D) DOPC-DSPC-Chol, and (E) 
POPC-DSPC-Chol systems. 
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Figure 6.2.   DAN-PC Spectral Shifts in DOPC-DPPC-Chol Membranes.  The 
emission maximum wavelength of DAN-PC-labeled DOPC-DPPC-Chol MLVs is 
plotted as a function of cholesterol composition for samples containing 0% ( ), 20% 
( ), 30% ( ), 40% ( ), 60% ( ), or 80% ( ) DPPC.   
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Figure 6.3.   DAN-PC Spectral Shifts in POPC-DPPC-Chol Membranes.  The 
emission maximum wavelength of DAN-PC-labeled POPC-DPPC-Chol MLVs is 
plotted as a function of cholesterol composition for samples containing 0% ( ), 20% 
( ), 40% ( ), 60% ( ), or 80% ( ) DPPC.   
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Figure 6.4.   DAN-PC Spectral Shifts in DLPC-DPPC-Chol Membranes.  The 
emission maximum wavelength of DAN-PC-labeled DLPC-DPPC-Chol MLVs is 
plotted as a function of cholesterol composition for samples containing 0% ( ), 20% 
( ), 40% ( ), 60% ( ), or 80% ( ) DPPC.   
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Figure 6.5.  DAN-PC Spectral Shifts in DPPC-Containing Systems.  (A) DOPC-
DPPC-Chol, (B) POPC-DPPC-Chol, and (C) DLPC-DPPC-Chol.  Points of 
discontinuity were determined from Figures 6.2, 6.3, and 6.4 using a piecewise 
continuous fit. 
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Figure 6.6.  DAN-PC Spectral Shifts in DOPC-DSPC-Chol Membranes.  The 
DAN-PC emission maximum is plotted as a function of cholesterol composition in 
DOPC-DSPC-Chol membranes at 30oC created along lines of constant DSPC 
composition (A) or constant DOPC composition (B).  Samples with constant DSPC 
compositions contained 5% ( ), 10% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), 
60% ( ), or 80%( ) DSPC.  Samples with constant DOPC compositions contained 
5% ( ), 10% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), 60% ( ), or 80%( ) DOPC.   
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Figure 6.7.  DAN-PC Spectral Shifts in POPC-DSPC-Chol Membranes.  The DAN-
PC emission maximum is plotted as a function of cholesterol composition in POPC-
DSPC-Chol membranes at 30oC created along lines of constant DSPC compositions 
(A) or constant POPC compositions (B).  Samples with constant DSPC compositions 
contained 0 ( ), 10 ( ), 20 ( ), 30 ( ), 40 ( ), 50 ( ), 60  (), or 80( )% DSPC.  
Samples with constant POPC compositions contained 5 ( ), 10 ( ), 20 ( ), 30 ( ), 
40 ( ), 50 ( ), 60 ( ), or 80( )% POPC.     
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Figure 6.8.  DAN-PC  Spectral Shifts in DSPC-Containig Systems.  (A) DOPC-
DSPC-Chol and (B) POPC-DSPC-Chol membranes at 30oC.  Samples were created 
along lines of either constant DOPC (A)/POPC (B) compositions ( ) or constant 
DSPC compositions ( ).   
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Figure 6.9.  DAN-PC Spectral Shifts in DOPC-DSPC-Chol Membranes at 60oC.  
DAN-PC emission maximum is plotted as a function of cholesterol composition in 
DOPC-DSPC-Chol membranes at 60oC created along lines of constant DSPC (A) or 
constant DOPC (B) compositions.  Samples with constant DSPC compositions 
contained 5% ( ), 10% ( ), 30% ( ), or 50% ( ) DSPC.  Samples with constant 
DOPC compositions contained 5% ( ), 10% ( ), 20% ( ), 30% ( ), 40% ( ), 50% 
( ), 60% ( ), or 80%( ) POPC.   
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Figure 6.10.  DAN-PC Spectral Shifts in POPC-DSPC-Chol Membranes at 60oC.  
DAN-PC emission maximum is plotted as a function of cholesterol composition in 
POPC-DSPC-Chol membranes at 60oC created along lines of constant DSPC (A) or 
POPC (B) composition.  Samples with constant DSPC compositions contained 0% 
( ), 10% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), 60%  (), or 80%( ) DSPC.  
Samples with constant POPC compositions contained 5% ( ), 10% ( ), 20% ( ), 
30% ( ), 40% ( ), 50% ( ), 60% ( ), or 80%( ) POPC. 
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Figure 6.11.  DAN-PC Spectral Shifts in DSPC-Containing Systems at 60oC.  The 
points of discontinuity in (A) DOPC-DSPC-Chol and (B) POPC-DSPC-Chol 
membranes at 60oC.  Samples were created along lines of either constant DOPC 
(A)/POPC (B) compositions ( ) or constant DSPC compositions ( ).   
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Figure 6.12.  Relation of the lo Transition and Average Tm.  (A) DPPC-containing 
systems: DOPC-DPPC-Chol ( ), POPC-DPPC-Chol ( ), and DLPC-DPPC-Chol  
( ).  (B) DSPC-containing systems: DOPC-DSPC-Chol ( ), and POPC-DSPC-Chol 
( ).   
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CHAPTER 7: DETECTION OF NANOSCALE DOMAINS BY FRET 
 
 
 
7.1  Introduction 
Because DAN-PC is excluded from the lo phase and DHE partitions 
predominately into the ld phase, this FRET pair can be used to detect and measure 
domain size.  In this work, we applied this FRET assay to four ternary systems 
containing a low-Tm phospholipid, a high-Tm phospholipid, and cholesterol.    
The high-Tm phospholipids used were DPPC (16:0) or DSPC (18:0) and the 
low-Tm phospholipids were DOPC (18:1), POPC (18:1-16:0), or DLPC (12:0).  This 
variety of systems allowed for comparison of phospholipid chain length and chain 
saturation on domain size and presence.     
The DOPC-DPPC-Chol and POPC-DPPC-Chol systems have been well-
studied.  DOPC-DPPC-Chol has been found to contain a two-phase region, and 
POPC-DPPC-Chol has been shown to contain no two-phase region (1-3).  DLPC-
DPPC-Chol has been shown to contain regions of phase coexistence, although the 
phase boundaries and exact nature of the phases remains in question (4).  The DSPC 
systems have been less well-studied than the DPPC systems; some evidence of phase 
coexistence has been detected in the DOPC-DSPC-Chol system (5) and some 
uncharacterized complex phase behavior has been found in the POPC-DSPC-Chol 
system (6).   
7.2  Experimental Overview 
 DAN-PC/DHE FRET was measured at various compositions in five different 
ternary systems: DOPC-DPPC-Chol, POPC-DPPC-Chol, DLPC-DPPC-Chol, DOPC-
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DSPC-Chol, and POPC-DSPC-Chol.  The experimental FRET profiles were fit with 
the model, as described in Chapter 4, to obtain domain radius estimates.   
7.2.1  Sample Preparation 
 Each sample contained a low-Tm lipid (DOPC, POPC, or DLPC), a high-Tm 
lipid (DPPC or DSPC), and cholesterol, and was labeled with DHE (as a fraction of 
cholesterol).  All samples were prepared using the RSE technique, and MLVs were 
used without further treatment.    
 FRET samples were created along lines of constant cholesterol composition 
with varying DPPC or DSPC compositions.  In the DOPC-DPPC-Chol system 
(Sample Set 7A), samples contained 20%, 30%, 40%, 50%, or 60% sterol and 0%, 
20%, 30%, 40%, 50%, or 60% DPPC.  In the POPC-DPPC-Chol system (Sample Set 
7B) and DLPC-DPPC-Chol system (Sample Set 7C), samples contained 20%, 40%, 
or 60% sterol and 0%, 20%, 40%, or 60% DPPC.  In the DOPC-DSPC-Chol system 
(Sample Set 7D), samples contained 20%, 30%, 40%, 50%, or 60% cholesterol and 
0%, 20%, 30%, 40%, 50%, or 60% DSPC.  In the POPC-DSPC-Chol system (Sample 
Set 7E), samples contained 20%, 30%, 40%, 50%, or 60% cholesterol and 0%, 20%, 
30%, 40%, 50%, or 60% DSPC.  Each FRET sample contained DAN-PC (as a 
fraction of the DOPC or POPC) at an ALR of 0.00 to 0.12 and DHE (as a fraction of 
cholesterol) at 5%.  The FRET sample compositions are shown in Table 7.1 and 
Figure 7.1.   
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Table 7.1.  Ternary FRET Sample Compositions 
Sample Low-Tm lipid High-Tm lipid % sterol % DPPC 
7A-1 DOPC DPPC 20% 0, 20, 30, 40, 50, or 60%
7A-2 DOPC DPPC 30% 0, 20, 30, 40, 50, or 60%
7A-3 DOPC DPPC 40% 0, 20, 30, 40, 50, or 60%
7A-4 DOPC DPPC 50% 0, 20, 30, 40, 50, or 60%
7A-5 DOPC DPPC 60% 0, 20, 30, 40, 50, or 60%
Sample Low-Tm lipid High-Tm lipid % sterol % DPPC 
7B-1 POPC DPPC 20% 0, 20, 40, or 60% 
7B-2 POPC DPPC 40% 0, 20, 40, or 60% 
7B-3 POPC DPPC 60% 0, 20, 40, or 60% 
Sample Low-Tm lipid High-Tm lipid % sterol % DPPC 
7C-1 DLPC DPPC 20% 0, 20, 40, or 60% 
7C-2 DLPC DPPC 40% 0, 20, 40, or 60% 
7C-3 DLPC DPPC 60% 0, 20, 40, or 60% 
Sample Low-Tm lipid High-Tm lipid % sterol % DSPC 
7D-1 DOPC DSPC 20% 0, 20, 30, 40, 50, or 60%
7D-2 DOPC DSPC 30% 0, 20, 30, 40, 50, or 60%
7D-3 DOPC DSPC 40% 0, 20, 30, 40, 50, or 60%
7D-4 DOPC DSPC 50% 0, 20, 30, 40, 50, or 60%
7D-5 DOPC DSPC 60% 0, 20, 30, 40, 50, or 60%
Sample Low-Tm lipid High-Tm lipid % sterol % DSPC 
7E-1 POPC DSPC 20% 0, 20, 30, 40, 50, or 60%
7E-2 POPC DSPC 30% 0, 20, 30, 40, 50, or 60%
7E-3 POPC DSPC 40% 0, 20, 30, 40, 50, or 60%
7E-4 POPC DSPC 50% 0, 20, 30, 40, 50, or 60%
7E-5 POPC DSPC 60% 0, 20, 30, 40, 50, or 60%
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7.2.2  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
All FRET samples were excited at 300 nm and the emission spectra were 
recorded from 325 to 550 nm.  All emission scans were conducted at 30oC.  The 
emission profiles were smoothed using a Savitsky and Golay protocol (7).     
7.2.3  Data Fitting 
Because no completed phase diagram with tie lines exists for any of the five 
systems used in this study, it was assumed that the phase boundaries and tie lines of 
the sphingomyelin-DOPC-Chol (1) system were valid for these systems.  DHE was 
assumed to partition like cholesterol and its partitioning between the two phases, do 
and dd, could therefore be determined from the phase diagram (1).  The unquenched 
donor lifetime was approximated as 1 ns (8).   
For each sterol composition, the sample containing 0% DPPC or DSPC, 
therefore lying well outside of the two-phase region, was assumed to contain no 
domains.  Restriction of energy transfer relative to this sample was taken as evidence 
of two-phase coexistence.  A value of Ro was determined for the 0% DPPC or 0% 
DSPC sample for each cholesterol compositions.  This value was assumed to be 
independent of phospholipid composition within the two-phase region, but was found 
to vary with cholesterol composition.  This assumption allowed for a single parameter 
fit, where the domain radius is the only fitted parameter.  Parameters used in the data 
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fitting for the DOPC-DPPC-Chol, DLPC-DPPC-Chol, DOPC-DSPC-Chol, and 
POPC-DSPC-Chol systems are shown in Tables 7.2, 7.3, 7.4, and 7.5 respectively.      
Experimental FRET efficiencies for samples within the two-phase region were 
compared to efficiencies predicted by the model (Section 4.3.3), and the domain 
radius, n, was varied to provide the best fit to the data.    
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Table 7.2. Parameters Used in DOPC-DPPC-Chol Data Fitting 
% sterol % DPPC do Ro (Å) 
20% 0% - 9.0 
20% 20% 0.7 9.0 
20% 30% 0.8 9.0 
20% 40% 0.8 9.0 
20% 50% 0.8 9.0 
20% 60% 0.7 9.0 
30% 0% - 11.0 
30% 20% 0.6 11.0 
30% 30% 0.7 11.0 
30% 40% 0.8 11.0 
30% 50% 0.8 11.0 
40% 0% - 11.0 
40% 20% 0.6 11.0 
40% 30% 0.6 11.0 
40% 40% 0.7 11.0 
60% 0% - 11.5 
60% 20% - 11.5 
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Table 7.3. Parameters Used in DLPC-DPPC-Chol Data Fitting 
% sterol % DPPC do Ro (Å) 
20% 0% - 12.5 
20% 20% 0.7 12.5 
20% 40% 0.8 12.5 
20% 60% 0.7 12.5 
40% 0% - 14.5 
40% 20% 0.6 14.5 
40% 40% 0.7 14.5 
60% 0% - 13.0 
60% 20% - 13.0 
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Table 7.4.  Parameters Used in DOPC-DSPC-Chol Data Fitting 
% sterol % DSPC do Ro (Å) 
20% 0% - 16.5 
20% 20% 0.7 16.5 
20% 30% 0.8 16.5 
20% 40% 0.7 16.5 
20% 50% 0.8 16.5 
20% 60% 0.8 16.5 
30% 0% - 14.5 
30% 20% 0.6 14.5 
30% 30% 0.7 14.5 
30% 40% 0.8 14.5 
30% 50% 0.8 14.5 
40% 0% - 14.5 
40% 20% 0.6 14.5 
40% 30% 0.6 14.5 
40% 40% 0.7 14.5 
50% 0% - 13.5 
50% 20% 0.7 13.5 
50% 30% 0.7 13.5 
60% 0% - 12.5 
60% 20% 0.7 12.5 
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Table 7.5.  Parameters Used in POPC-DSPC-Chol Data Fitting 
% sterol % DSPC do Ro (Å) 
20% 0% - 17.0 
20% 20% 0.7 17.0 
20% 30% 0.8 17.0 
20% 40% 0.8 17.0 
20% 50% 0.8 17.0 
20% 60% 0.8 17.0 
30% 0% - 15.5 
30% 20% 0.6 15.5 
30% 30% 0.7 15.5 
30% 40% 0.8 15.5 
30% 50% 0.8 15.5 
40% 0% - 14.0 
40% 20% 0.6 14.0 
40% 30% 0.6 14.0 
40% 40% 0.7 14.0 
50% 0% - 13.0 
50% 20% 0.7 13.0 
50% 30% 0.7 13.0 
60% 0% - 12.0 
60% 20% - 12.0 
 
 103
7.3  Results 
7.3.1  Domain Sizes in the DOPC-DPPC-Chol System 
 The DAN-PC/DHE FRET profiles of DOPC-DPPC-Chol membranes and 
their fitted domain sizes are shown in Figure 7.2.  At 30oC, the system shows 
evidence of two-phase coexistence at many of the compositions studied.   
Domains ranging from 3 nm to 6 nm were detected in the samples containing 
20% sterol (Figure 7.2A), domains ranging from 3.5 to greater than 15 nm were 
detected in the 30% sterol samples (Figure 7.2B), and domains ranging from 3.5 to 
5.5 nm were detected in the 40% sterol samples (Figure 7.2C).  The 60% sterol 
samples contained no domains.   
7.3.2.  Domain Sizes in the POPC-DPPC-Chol System 
   Figure 7.3 shows the FRET profiles of POPC-DPPC-Chol membranes at 
30oC.  For each cholesterol composition, the FRET profiles do not vary significantly, 
indicating that no domains are present at these compositions.  One exception to this is 
the 20% sterol, 60% DPPC sample, which shows a restricted energy transfer.  This 
may be evidence of liquid-liquid domain formation; however, lack of phase 
boundaries and tie line information make it impossible to predict a domain size for 
this composition.   
7.3.3  Domain Sizes in the DLPC-DPPC-Chol System 
The FRET profiles and fitted domain sizes in the DLPC-DPPC-Chol system 
are shown in Figure 7.4.  In the samples containing 20% cholesterol (Figure 7.4A), 
domains ranging from 3.0 to 14.0 nm were detected, and domains ranging from 3.5 to 
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5.5 nm were detected in samples containing 40% cholesterol (Figure 7.4B).  No 
domains were detected in the samples containing 60% cholesterol (Figure 7.4C).     
7.3.4  Domain Sizes in the DOPC-DSPC-Chol System 
DAN-PC/DHE FRET results in DOPC-DSPC-Chol membranes at 30oC are 
shown in Figure 7.5.  Evidence of two-phase coexistence is observed over a wide 
range of compositions in the DOPC-DSPC-Chol system.  Domains ranging in size 
from 3.5 nm to greater than 15.0 nm were detected in membranes containing 20% 
sterol (Figure 7.5A).  (The resolution of the model is limited to domain sizes of about 
10 times the Forster distance.)  Membranes containing 30% sterol contain domains 
ranging from 4.5 to 6.5 nm (Figure 7.5B) and membranes containing 40% sterol 
contain domains ranging from 3.5 to 5.0 nm (Figure 7.5C).   
 Slight restriction of energy transfer is observed in membranes containing 50% 
(Figure 7.5D) and 60% sterol (Figure 7.5E).  These FRET profiles correspond to 
domain sizes ranging from 1.0 to 2.5 nm.  Because the average diameter of a PC 
molecule is about 8Å, these domain sizes are interpreted as nonideal mixing, rather 
than actual domain formation.     
7.3.5  Domain Sizes in the POPC-DSPC-Chol System 
 The POPC-DSPC-Chol membranes also show evidence of phase coexistence 
over a range of compositions, as seen in Figure 7.6.  In membranes containing 20% 
sterol, domains of 7.0 to 9.5 are detected (Figure 7.6A).  Domains ranging from 5.0 to 
8.0 nm are detected in membranes containing 30% sterol (Figure 7.6B), and domains 
ranging from 4.0 to 5.0 nm are detected in membranes containing 40% sterol (Figure 
7.6C).  Slight FRET restrictions are observed in membranes containing 50% sterol 
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(Figure 7.6D), indicating a region of nonideal mixing.  Membranes containing 60% 
sterol contain no domains (Figure 7.6E).     
7.4  Discussion 
Figure 7.7 shows a summary of the predicted domain sizes in the five ternary 
systems studied here.  Domains are observed in all of the systems except the POPC-
DPPC-Chol system. 
7.4.1  Effect of Phospholipid Chain Saturation on Domain Size   
DPPC-Containing Systems.  In the systems containing DPPC that were 
studied, the saturation of the low-Tm component can have a significant effect on the 
presence of domains.  A large region of ld  to  lo phase coexistence is observed in 
the DOPC-DPPC-Chol system but not in the POPC-DPPC-Chol system.  However, 
phase coexistence is again observed in the DLPC-DPPC-Chol system.   It is apparent 
that increasing the saturation of the low-Tm lipid can have a significant effect on 
domain presence, but it is not the only factor at play. 
DSPC-Containing Systems.  In contrast, the saturation of the low-Tm 
component had very little effect on domain presence in the two DSPC systems.  Both 
systems contained a region of phase coexistence at approximately the same 
composition range.   
Saturation did have an effect on domain sizes and the domain size variation 
with composition, with some slightly larger domains detected in the DOPC-DSPC-
Chol system, relative to the POPC-DSPC-Chol system. Domains ranging from 3.5 to 
15 nm were detected in the DOPC-DSPC-Chol system, and domains ranging from 4.0 
to 9.5 nm were detected in the POPC-DSPC-Chol system.   
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7.4.2  Effect of Phospholipid Chain Length on Domain Size 
Variation of the saturated phospholipid chain length has some effect on 
domain size and presence although, as in the case of variation of phospholipid chain 
saturation, the effect is slightly ambiguous. 
DOPC-Containing Systems.  In the two DOPC-containing systems, domains 
of very similar sizes are observed, and the variation in domain size with composition 
is similar.  In these two systems, the length of the fully saturated component has little, 
if any, effect on domain size and presence.    
POPC-Containing Systems.  However, in the two POPC systems, a 
significant difference was observed when the saturated component was DSPC versus 
when it was DPPC.  No phase separation was observed at most compositions in the 
POPC-DPPC-Chol system, but a large two-phase region was observed in the POPC-
DSPC-Chol system.     
7.4.3  Summary of Factors Affecting Domain Formation 
One theory to explain why the lack of two phase coexistence in DPPC-POPC-
Chol membranes and the presence of two-phase coexistence in SM-POPC-Chol 
membranes is the ability of SM to form hydrogen bonds with cholesterol (1,9-11).  
However, we detected domains in a POPC system that does not contain SM, 
suggesting that there must be another effect responsible for domain formation in 
addition to the hydrogen-bonding effect.   
Additionally, differences in Tm between the low- and high-Tm lipids are not 
the sole determinate of domain formation or size.  In systems with very large 
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differences in Tm, domains form, but in systems with smaller Tm differences, domains 
may or may not form, as demonstrated in Table 7.6.   
The difference in line tension in ordered domains of DPPC compared to 
ordered domains of DSPC may be the factor that drives domain formation in PC-
systems in which hydrogen-bonding is not possible.  This difference in height creates 
a difference in line tension based on the elastic theory of line tension (12).  In PC-
systems containing no domains (POPC-DPPC-Chol), the increase in line tension by 
replacing DPPC with DSPC causes domains to form; however, in PC-systems 
containing domains (DOPC-DPPC-Chol), the increase in line tension by replacing 
DPPC with DSPC has very little effect on domain size. 
This line tension effect is also believed to be the reason that domains are not 
observed in the POPC-DPPC-Chol system, but are observed in both the DOPC-
DPPC-Chol and DLPC-DPPC-Chol systems.  The POPC-DPPC-Chol system most 
likely has the lowest line tension of the three systems because of the asymmetric 
nature of the POPC chains allowing it to act as a lineactant.  This molecule may act 
to alleviate the line tension present in the DOPC-DPPC-Chol system due to the di-
unsaturation of DOPC and the DLPC-DPPC-Chol system due to the height mismatch 
between DLPC and DPPC.     
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Table 7.6.  Difference in Tm Between Saturated and Unsaturated Lipids 
High-Tm Component Low-Tm Component
Lipid Tm (oC) Lipid Tm (oC)
∆Tm (oC) Domains? 
SM 42oC (13)  POPC -2oC (14) 44oC Yes (1)
SM 42oC (13)  DOPC -20oC (14) 62oC Yes (1)
DPPC 41oC (14)  DLPC -1oC (14) 42oC Yes
DPPC 41oC (14)  POPC -2oC (14) 43oC No (1,15)
DPPC 41oC (14) DOPC -20oC (14) 61oC Yes (1,15)
DSPC 55oC (14)  POPC -20oC (14) 75oC Yes
DSPC 55oC (14)  DOPC -2oC (14) 57oC Yes
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An approximate evaluation of line tension in these five systems was 
performed, using the elastic theory of line tension (12), and results are included in 
Table 7.7.  For this evaluation, it was assumed that the height difference in the 
DOPC-DPPC-Chol system is 0.5 nm (16) and that the height difference in the POPC-
DPPC-Chol system is 0.0 nm.  From these assumptions, height differences of all of 
the other systems could be determined using bond length calculations.  DSPC is about 
0.3 nm taller than DPPC, and DPPC is about 0.6 nm taller than DLPC.  Based on this 
approximation, the system with the highest line tension is DOPC-DSPC-Chol system 
with a line tension of 5.3 pN, and the system with the lowest line tension is the 
POPC-DSPC-Chol system. 
The approximated line tension correlates more with the observed domain sizes 
than does the difference in Tm; the largest domain sizes were observed in the systems 
with the largest line tension and the smallest domain sizes were observed in the 
POPC-DSPC-Chol system which has the second lowest line tension.  The system 
with the lowest line tension (POPC-DPPC-Chol) does not contain any domains.   
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Table 7.7.  Phase Transition Temperatures and Line Tension 
System Domain Size Range ∆Tm (oC) Line tension (pN)
DOPC-DPPC-Chol 3.0  15.0 nm 61 oC 2.3 
POPC-DPPC-Chol None 50 oC 0.0 
DLPC-DPPC-Chol 3.0  14.0 nm 42 oC 3.2 
DOPC-DSPC-Chol 3.5  15.0 nm 75 oC 5.3 
POPC-DSPC-Chol 4.0  9.5 nm 64 oC 0.9 
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7.4.4  Comparison with Other Studies 
The region of two-phase coexistence observed in the DOPC-DPPC-Chol 
system by FRET occurs at similar compositions as the region observed by 
fluorescence microscopy (1,2,17) and NMR (17).  However, the domains detected in 
this work are on the order of nanometers, while those in the fluorescence microscopy 
work are on the order of microns (1,2,17) and tens of nanometers in the NMR study 
(17). 
POPC-DPPC-Chol has been shown to contain no domains at any composition 
(1), and the results presented in this work mostly agree with that observation.  
However, one small region of undefined phase coexistence was observed at low sterol 
and high DPPC compositions in this work that was not detected previously by 
fluorescence microscopy. 
Domain existence in the DLPC-DPPC-Chol system has been shown 
previously (4); however, in this study, a larger region of phase coexistence was 
identified.    
The region of two-phase coexistence that was observed in DOPC-DSPC-Chol 
membranes in this FRET study is similar qualitatively to a fluorescence 
microscopy/FRET study on the same system (5).  A separate fluorescence microscopy 
study found evidence of micron-scale domains in 50:50 mixtures of DOPC and DSPC 
at cholesterol compositions of 20% and 33% (3).  Domains in the microscopy studies 
were micron-scale (3,5), while those in this FRET study were nanometer-scale (5).   
Few studies have looked at the POPC-DSPC-Chol system, but one found a 
region of so-lo coexistence at cholesterol compositions below 20% with complex, 
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unspecified phase behavior outside of this region (6).  We found that this complex 
behavior is nanoscale domain formation within a lo-ld coexistence region that occurs 
at similar compositions as in the DOPC-DSPC-Chol system.   
7.4.5  Additional Observations 
A surprising Ro behavior was observed throughout this study.  Ro was found 
to change with cholesterol composition, most likely due to the induction of 
phospholipid order by the cholesterol.  Of the factors impacting Ro (quantum yield, 
spectral overlap, refractive index, and orientation factor) the one most likely to vary 
due to cholesterol content is the orientation factor, κ2.  It has been shown that DAN-
PC resides at different depths within the membrane depending on the cholesterol 
content of the membrane (18); this behavior could cause variations in κ2 as DAN-PC 
shifts in the membrane.  It is common practice to assume that Ro is a constant for a 
particular FRET pair, but this observation indicates that this is not a valid assumption.  
Forster distance in DOPC-DPPC-Chol membranes was found to vary from 9.0 Å to 
12.0 Å; in POPC-DPPC-Chol membranes the variation was less severe (10.0  10.5 
Å), but it differed from values in the DOPC-DPPC-Chol membranes.   
7.5  Conclusions 
It is difficult to decouple the effects of phospholipid chain saturation and 
chain length on domain size.  Rather, it appears that differences in line tension due to 
variation in chain saturation and chain length is what most greatly impacts domain 
formation and domain size.  Even a slight increase in line tension (a few pN) can 
overcome the inhibition of domain formation in systems, such as the POPC-DPPC-
Chol system, which do not form domains.  Systems containing higher line tension 
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were also found to contain slightly larger domain sizes than those with lower line 
tension.       
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Figure 7.1.  Ternary FRET Sample Compositions.  (A) DOPC-DPPC-Chol, (B) 
POPC-DPPC-Chol, (C) DLPC-DPPC-Chol, (D) DOPC-DSPC-Chol, and (E) POPC-
DPPC-Chol membranes.    
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Figure 7.2.  FRET in DOPC-DPPC-Chol Membranes.  FRET profiles and fitted 
domain sizes of DAN-PC- and DHE-labeled DOPC-DPPC-cholesterol MLVs are 
shown.  20% sterol samples (7.2A) contained 0% ( ), 20%, ( ) 30% ( ), 40% ( ), 
50% ( ), or 60% ( ) DPPC.  30% sterol samples (7.2B) contained 0% ( ), 20% ( ), 
30% ( ) , 40% ( ), or 50% ( ) DPPC.  40% sterol samples (7.2C) contained 0% 
( ), 20% ( ), 30% ( ), 40% ( ) DPPC, and the 60% sterol samples (7.2D) 
contained 0% ( ) or 20% ( ) DPPC.   
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Figure 7.3.  FRET in POPC-DPPC-Chol Membranes.  FRET profiles of DAN-PC- 
and DHE-labeled POPC-DPPC-cholesterol MLVs are shown.  20% sterol samples 
(7.3A) contained 0% ( ), 20%, ( ) 40% ( ), or 60% ( ) DPPC.  40% sterol samples 
(7.3B) contained 0% ( ), 20% ( ), 40% ( ) DPPC, and the 60% sterol samples 
(7.3C) contained 0% ( ) or 20% ( ) DPPC.   
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Figure 7.4.  FRET in DLPC-DPPC-Chol Membranes.  FRET profiles of DAN-PC- 
and DHE-labeled DLPC-DPPC-cholesterol MLVs is shown.  20% sterol samples 
(7.4A) contained 0% ( ), 20%, ( ) 40% ( ), or 60% ( ) DPPC.  40% sterol samples 
(7.4B) contained 0% ( ), 20% ( ), 40% ( ) DPPC, and the 60% sterol samples 
(7.4C) contained 0% ( ) or 20% ( ) DPPC.   
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Figure 7.5.  FRET in DOPC-DSPC-Chol Membranes.  FRET profiles in DOPC-
DSPC-Chol membranes at 30oC is shown.  The membranes contained 20% sterol (A), 
30% sterol (B), 40% sterol (C), 50% sterol (D), or 60% sterol (E).  Within each sterol 
composition, samples contained 0% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), or 
60% ( ) DSPC. 
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Figure 7.6.  FRET in POPC-DSPC-Chol Membranes.  FRET profiles in POPC-
DSPC-Chol membranes at 30oC are shown.  The membranes contained 20% sterol 
(A), 30% sterol (B), 40% sterol (C), 50% sterol (D), 60% sterol (E).  Within each 
sterol composition, samples contained 0% ( ), 20% ( ), 30% ( ), 40% ( ), 50% ( ), 
or 60% ( ) DSPC. 
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Figure 7.7.  Summary of Ternary FRET Results.  (A) DOPC-DPPC-Chol 
membranes, (B) POPC-DPPC-Chol membranes, (C) DLPC-DPPC-Chol membranes, 
(D) DOPC-DSPC-Chol membranes and (E) POPC-DSPC-Chol membranes at 30oC.   
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CHAPTER 8: KINETICS OF DOMAIN FORMATION 
 
 
 
8.1  Introduction 
 The growth and depletion of rafts has significant implications in cellular 
functioning.  Coalescence of small, unstable rafts has been suggested as a signaling 
mechanism which initiates certain processes (1-3).  It has been proposed that raft 
coalescence and growth in natural membranes is regulated by the cell; for example, 
the membrane may be at a composition that is close to the phase coexistence region, 
allowing raft formation to begin with just a slight change in lipid composition (4).  As 
a result, rafts in natural cell membranes remain small and transient.   
It has been shown in model membranes that domain growth occurs rapidly 
and via a nucleation-growth method when temperature is increased to bring the 
membrane into the two-phase region (5-7).  Here, we investigate domain growth 
through a more biologically-relevant process, by changing lipid composition, to 
understand the kinetics of domain formation in model membranes.       
8.2  Experimental Overview 
 Two sets of experiments were performed in this work.  In the first set, samples 
containing 40% sterol and DOPC were mixed with samples containing only DPPC in 
order to look at the kinetics of domain formation as the sample composition passes 
into and through the two-phase region.  The second set involved mixing samples 
containing 40% sterol and DPPC with samples containing only DOPC to look at the 
kinetics of domain dissipation upon addition of a lineactant (DOPC).       
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8.2.1  Sample Preparation 
 In order to look at the kinetics of domain growth, four pairs of samples were 
created.  The first sample of the pair contained 40% sterol (cholesterol and DHE),  
60% DOPC, and DAN-PC.  The second sample of the pair contained 100% DPPC.  
The two samples were mixed in a ratio to provide the desired final lipid composition.  
The mixing ratios and final lipid compositions are shown in Table 8.1.  Initial and 
final lipid compositions are shown in Figure 8.1. 
 Domain dissipation samples were created in a similar manner to domain 
growth samples.  Three pairs of samples were created, with one of the samples 
containing 95% DOPC, 5% DHE, and DAN-PC (ALR of 0.00 to 0.12) and the other 
containing 24% sterol, 36% DPPC, and 40% DOPC.  The samples were mixed in a 
ratio to provide the final lipid composition, as shown in Table 8.1.  Initial and final 
lipid compositions are shown in Figure 8.2.     
 125
     
 
 
Table 8.1.  Domain Growth Sample Compositions 
Domain Growth Samples
Final Composition Sample ID Sample ratio 
% sterol % DOPC % DPPC
8A 1:0 40% 60% 0% 
8B 3:1 30% 45% 25%
8C 1:1 20% 30% 50%
8D 1:3 10% 15% 75%
Domain Dissipation Samples
Final Composition Sample ID Sample ratio 
% sterol % DOPC % DPPC
8E 1:0 24% 40% 36%
8F 3:1 19.25% 41.75% 27%
8G 1:1 14.5% 55.5% 18%
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8.2.2  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
All FRET samples were excited at 300 nm, and the emission spectra were 
recorded from 325 to 550 nm.  All emission scans were conducted at 30oC.  The 
emission profiles were smoothed using a Savitsky and Golay protocol (8).     
8.3  Results 
8.3.1  Domain Growth Dynamics 
 Domain growth dynamics are shown in Figures 8.3 through 8.6.  Each sample 
set was created with an identical lipid composition of 40% sterol and 60% DOPC.  
Vesicles composed of 100% DPPC were added in various proportions to alter the 
final lipid composition.  As the vesicles and lipids mix, the lipid composition moves 
from a point that is entirely ld into the two-phase region, where domains form and 
grow.  The domain growth was observed through the variation in FRET profile with 
time.       
Sample 8A was used as a control, as its final composition is the same as its 
initial composition.  The mixing ratio was 1:0; that is, no pure DPPC vesicles were 
added to the DOPC/Chol vesicles.  The FRET profile, as shown in Figure 8.3, does 
not vary throughout the time-scale of the experiment.   
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 Sample Set 8B was mixed in a DOPC/Chol:DPPC vesicle ratio of 3:1 so that 
the final lipid composition was 30% sterol, 45% DOPC, and 25% DPPC.  The FRET 
profile (Figure 8.4) decreases slightly with time as domains form and grow.   
 In Sample Set 8C, the DOPC/Chol : DPPC vesicle ratio was 1:1, resulting in a 
final lipid composition of 20% sterol, 30% DOPC, and 50% DPPC.  The FRET 
profile for this sample set (Figure 8.5) decreases to a slightly greater extent with time 
than in Sample Set 8B because of additional domain growth as the final lipid 
composition is further into the two-phase region.   
 Sample Set 8D was mixed so that the final lipid composition was 10% sterol, 
15% DOPC, and 75% DPPC.  The FRET profile variation with time (Figure 8.6) 
indicates significant domain growth through the eight-hour experiment.  The FRET 
profile of a sample with the final composition is included on the graph.  Domains of 
6.5 nm are predicted for this steady-state sample.  
 Domain sizes for the FRET profiles in Figure 8.6 were determined using the 
model and the resulting predicted domain sizes as a function of time are shown in 
Figure 8.7.  The final expected domain size is 6.5 nm and domains reach a value of 6 
nm within the experimental time-frame of 8 hours.         
8.3.2  Domain Dissipation Dynamics 
 Figures 8.8 through 8.10 show the domain dissipation dynamics.  All of the 
samples sets were created with the same initial lipid composition: 24% sterol, 36% 
DPPC, and 40% DOPC.  DOPC vesicles were added in various proportions so that 
the final lipid composition of each sample set was different.     
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 The control sample set, Sample Set 8E, is shown in Figure 8.8.  The FRET 
profile is low, indicating the presence of sizeable domains.  The composition of this 
sample remains constant throughout the experiment, and this is reflected in the lack of 
change in the FRET profile.   
 Results from Sample Set 8F are shown in Figure 8.9.  The FRET profile is 
fairly constant throughout the three-hour experiment suggesting no domain 
dissipation.  However, comparison of Figure 8.9 with Figure 8.8 reveals a striking 
difference in the initial FRET values.  FRET in Sample Set 8F is much higher than in 
Sample Set 8E, indicating that domain dissipation is an extremely fast process and 
happens before the fluorimeter reading is recorded. 
 Likewise, Sample Set 8G (Figure 8.10) shows a higher FRET profile than 
either Sample Set 8F or 8E.  This sample shows a slight decrease in FRET profile 
during the time-scale of the experiment.  Domain dissipation would be marked by an 
increase in FRET profile, rather than an increase, suggesting that this slight change is 
simply due to probe spreading as the lipids mix.   
 Comparison of the FRET profiles in Figures 8.8, 8.9, and 8.10 provides an 
intriguing observation.  Although each sample began with the same lipid 
composition, the initial (t=0) FRET profile increases from Figure 8.8 to Figure 8.10.  
This behavior suggests that the domain size decrease is an extremely fast process, 
which is unable to be captured via steady-state FRET.   
8.4  Discussion 
 This work demonstrated striking differences between the time-scales of 
domain growth and domain dissipation.  We found that domains grow to reach their 
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final size within several hours, but that domains dissipate within several seconds.  
Domains grow slowly, and the growth is readily tracked via steady-state fluorescence 
spectroscopy.  Dissipation of domains appears to occur much more quickly however, 
with domains reaching a final value before the fluorimeter reading is recorded.  In 
order to fully study this question, a technique with a faster response time must first be 
identified.      
8.5  Conclusions 
Domain growth and dissipation are clearly not simply opposite processes.  
Each occurs with its own characteristic time-scale that is significantly different 
depending on whether domains are growing or shrinking.     
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Figure 8.1.  Domain Growth Sample Compositions.  All four samples initially 
contained 40% sterol and 60% DOPC; 100% DPPC vesicles were added in a ratio to 
bring the final lipid composition to the point marked by the arrow.   
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Figure 8.2.  Domain Dissipation Sample Compositions.  All three samples initially 
contained 25% sterol and 40% DOPC and 35% DPPC; 100% DOPC vesicles were 
added in a ratio to bring the final lipid composition to the point marked by the arrow.   
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Figure 8.3.  Domain Growth A.  FRET profile variation due to domain growth in 
vesicles with an initial composition of 40% sterol and 60% DOPC and a final 
composition of 40% sterol, 60% DOPC, and 0% DPPC.     
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Figure 8.4.  Domain Growth B.  FRET profile variation due to domain growth in 
vesicles with an initial composition of 40% sterol and 60% DOPC and a final 
composition of 30% sterol, 45% DOPC, and 25% DPPC.     
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Figure 8.5.  Domain Growth C.  FRET profile variation due to domain growth in 
vesicles with an initial composition of 40% sterol and 60% DOPC and a final 
composition of 20% sterol, 30% DOPC, and 50% DPPC.     
 135
 
 
 
 
Figure 8.6.  Domain Growth D.  FRET profile variation due to domain growth in 
vesicles with an initial composition of 40% sterol and 60% DOPC and a final 
composition of 10% sterol, 15% DOPC, and 75% DPPC.     
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Figure 8.7.  Domain Sizes.  Predicted domain sizes are plotted as a function of time 
for Sample Set D (Figure 8.6). 
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Figure 8.8.  Domain Dissipation A.  FRET profile variation due to domain 
dissipation in vesicles with an initial composition of 24% sterol, 36% DPPC, and 
40% DOPC and a final composition of 24% sterol, 36% DPPC, and 40% DOPC.   
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Figure 8.9.  Domain Dissipation B.  FRET profile variation due to domain 
dissipation in vesicles with an initial composition of 24% sterol, 36% DPPC, and 
40% DOPC and a final composition of 19.25% sterol, 27% DPPC, and 41.75% 
DOPC.   
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Figure 8.10.  Domain Dissipation C.  FRET profile variation due to domain 
dissipation in vesicles with an initial composition of 24% sterol, 36% DPPC, and 
40% DOPC and a final composition of 14.5% sterol, 18% DPPC, and 55.5% DOPC.   
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CHAPTER 9: KINETICS OF CHOLESTEROL REMOVAL BY β-CD 
 
 
 
9.1  Introduction 
 Cyclodextrins are a group of cyclic oligosaccharides containing six, seven, or 
eight units (α-, β-, or γ-cyclodextrin, respectively).  Because of the arrangement of 
molecules, the interior of all cyclodextrins is hydrophobic, and for this reason, they 
are often used to transport water-insoluble molecules.  The size of the interior cavity 
depends on the number of saccharide units, and it has been found that the cavity of β-
cyclodextrin (β-CD) (7.5 Å) is ideal for the transportation of cholesterol (1-3). 
Although β-CD is often used by cell biologists to modulate the cholesterol 
levels of cell membranes, little is known about the way in which cholesterol is 
removed (or added) to the membrane by β-CD.  One prominent question is whether 
cholesterol is preferentially removed from the ld or lo phase.  The answer to this 
question depends on the influence of packing on cholesterol removal, as well as the 
impact of cholesterol composition on cholesterol removal.   
It has been shown that removal of cholesterol by β-CD from pure sterol 
monolayers depends directly on the lateral surface pressure of the monolayer, with 
higher surface pressure resulting in higher removal rates (4).  This behavior is 
observed in pure cholesterol membranes, however, and its extension to cholesterol-
lipid membranes is unknown.  In cholesterol-lipid systems, the rate of cholesterol 
removal from cholesterol-DPPC has been found to increase as the mole fraction of 
cholesterol increases (4), indicating that the complexation reaction is dependent on 
cholesterol content by some order.  Additionally, cholesterol removal was determined 
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to be much faster in DPPC monolayers than in SM monolayers (4,5), possibly due to 
the enhanced interaction of cholesterol with SM via hydrogen-bonding. 
These behaviors indicate the importance of the local cholesterol environment 
in determination of kinetic behavior.  However, knowledge about the difference in 
removal from ld versus lo phases and its implication in the use of cholesterol removal 
as a means to determine cellular process dependence on cholesterol and/or raft 
presence is severely lacking.  For example, two recent studies have found that 
cholesterol is removed by β-CD from DOPC-SM-Chol membranes at two different 
rates.  This behavior is most likely due to the presence of both ld and lo phases, 
although it is not interpreted in terms of phase behavior in the articles (1,6,7).  In this 
work, we apply our knowledge of lipid phase behavior in an attempt to elucidate 
differences in cholesterol efflux from ld and lo membranes.       
9.2  Experimental Overview 
 Two initial experiments were performed to investigate the effect of cholesterol 
removal by β-CD on DAN-PC spectral shifts and DAN-PC/DHE FRET in a binary 
DMPC-Chol system.  In addition, equilibrium analysis was performed on FRET 
samples in the DMPC-Chol and POPC-DPPC-Chol systems.   
9.2.1  Sample Preparation 
 Several types of samples were used in the cyclodextrin studies.  Initial work 
was performed with DMPC-Chol samples to characterize the effect of β-CD on the 
membranes and determine the most effective route to obtain kinetic data.  Later work 
was performed with POPC-DPPC-Chol samples to obtain kinetic data in a more 
physiologically relevant system.     
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 DMPC-Chol spectral shift samples (Sample Set 9A) were created with 
varying amounts of cholesterol, DAN-PC at an ALR of 0.03, and DMPC.  Two mL of 
the vesicle solution (with a total lipid concentration of 1 mM) was mixed with one 
mL of the β-CD solution (with a concentration of 20 mg/mL). 
DMPC-Chol FRET samples (Sample Set 9B) were created with varying 
amounts of cholesterol and DMPC and were labeled with 5% DHE and DAN-PC at 
an ALR of 0.00 to 0.12.  Two mL of the vesicle solution (total lipid concentration of 
1mM) was mixed with one mL of β-CD in DI water (20 mg/mL).   
The first set of equilibrium analysis samples (Sample 9C) was created to 
contain 5% or 50% sterol and DMPC.  Each sample was labeled with DAN-PC (ALR 
of 0.00 or 0.12) and DHE (5%).  The total lipid concentration of the samples was 0.25 
mM.  Two mL of the vesicle solution was mixed with one mL of β-CD in DI water 
(20 mg/mL).   
 A second set of equilibrium analysis samples (Sample Set 9D) was created 
with 30% sterol (all DHE), 5 or 50% DPPC, and POPC.  These samples were labeled 
with DAN-PC at an ALR of 0.00 or 0.12.  Two mL of the vesicle solutions (total lipid 
concentration of 0.25 mM) was mixed with one mL of β-CD in DI water (20 mg/mL). 
 Table 9.1 contains a summary of the sample compositions.   
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Table 9.1.  β-CD Sample Compositions  
Sample Analysis Lipid System % Sterol % DPPC
9A Spectral Shift DMPC-Chol 0 to 60% NA 
9B FRET DMPC-Chol 0 to 60% NA 
9C FRET DMPC-Chol 5 or 50% NA 
9D FRET POPC-DPPC-Chol 30% 5 or 50%
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9.2.2  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
All FRET samples were excited at 300 nm, and the emission spectra were 
recorded from 325 to 550 nm.  The spectral shift samples were excited at 350 nm, and 
the emission spectra were recorded from 400 to 600 nm.  All emission scans were 
conducted at 30oC.  The emission profiles were smoothed using a Savitsky and Golay 
protocol (8).     
9.3  Results 
9.3.1  DMPC-Chol Spectral Shift Results 
 The spectral shift behavior of the DMPC-Chol membranes displays two 
distinct behaviors, depending on the phase of the membrane.  Samples containing 10 
or 20% cholesterol (therefore within the two-phase region) display a fairly constant 
DAN-PC emission max after addition of β-CD, as seen in Figure 9.1.     
 Samples that are completely lo display an increase in DAN-PC emission 
maximum as cholesterol is removed by β-CD, as shown in Figure 9.2.  The DAN-PC 
emission maximum increases significantly during the first five minutes after β-CD 
addition, and then levels off to a more constant value.   
 The behavior that is observed in the DMPC-Chol samples can be related to 
previously observed DAN-PC spectral shift behavior (Chapter 6).  Through the two-
phase region, the DAN-PC emission maximum is constant, regardless of the 
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cholesterol content of the membrane, due to the exclusion of DAN-PC from the lo 
phase.  The DAN-PC emission maximum is constant after β-CD addition simply 
because DAN-PC is insensitive to changes in cholesterol content in this 
compositional region.   Likewise, the increase in DAN-PC emission maxima (or red 
shift) that is observed for samples within the lo region as cholesterol is removed by β-
CD is the counterpart to the blue shift that is observed in lo membranes as more 
cholesterol is added to the membrane.       
 In summary, the DAN-PC spectral shift technique is not ideal for kinetic 
analysis, as it is completely insensitive to any changes in cholesterol content within 
any phase except the lo phase.    
9.3.2  DMPC-Chol FRET Results 
 The DMPC-Chol FRET behavior after β-CD addition also displays two types 
of behavior depending on the initial cholesterol composition of the membranes.   
 Samples containing 10% or 20% cholesterol (within the two-phase region) 
undergo an increase in FRET upon β-CD addition, as seen in Figure 9.3.  The 
increase is initially steep and then plateaus within the 30 minute experiment.   
 Samples containing 30 to 40% cholesterol display an opposite behavior; 
FRET efficiency decreases after β-CD addition (Figure 9.4).  The decrease is most 
pronounced in the early part of the experiment and levels off within the 30 minute 
experiment.      
 As with the spectral shift samples, these FRET results can be explained by 
DMPC-Chol phase behavior.  The FRET efficiency as a function of cholesterol was 
shown to contain a minimum value within the two-phase region (Figure 5.4) due to 
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probe separation as domains form.  The 10% and 20% samples are on the left side of 
this minimum, and therefore, as cholesterol is removed by β-CD, FRET efficiency 
increases.  The samples containing 30 to 40% cholesterol are to the right of the 
minimum FRET value; as cholesterol is removed by β-CD, FRET efficiency 
decreases slightly.   
 The FRET assay provides a means of determining the kinetics of cholesterol 
removal by cyclodextrin.  However, these results indicate the need for careful data 
interpretation, as results are dependent on the phase behavior of the system.  
9.3.3  Equilibrium Analysis of DMPC-Chol FRET Data  
 The removal of sterol (DHE) by β-CD in the ld phase and in the lo phase was 
determined through an equilibrium analysis assuming that empty β-CD removes 
sterol from the membrane and full β-CD adds sterol to the membrane: 
                         k1 
Chol + CD           CD-Chol     (1) 
                         k-1  
With the forward rate constant k1 and the reverse rate constant k-1.  Because β-CD is 
added in extreme excess (17.6 mmol β-CD: 2.5 x 10-5  2.5 x 10-4 mmol chol), it can 
be assumed that its concentration does not change during the reaction.  In this case,  
[ ] [ ]CholCDkk
dt
chold
−−=−
−11      (2) 
And the FRET profiles can be modeled:     
[ ] ( )[ ]tkkxEtE eeq 11exp%)(% −+ +−+=    (3) 
where %Eeq is the equilibrium FRET efficiency value and xe is the difference between 
the initial %E (%E(t=0)) and %Eeq (9). 
 148
 Figures 9.5 and 9.6 show the change in %E after β-CD addition for a sample 
with an initial sterol (DHE) composition of 5% (ld) and a sample with an initial sterol 
(DHE) composition of 50% (lo), respectively along with the best fit equilibrium 
curves for each sample.  Equilibrium analysis reveals that k1 + k-1 for the ld sample is 
0.048 and for the lo sample is 0.015.   
Analysis of these results is complicated for two reasons.  In the DMPC-Chol 
system, it is impossible to de-couple any sterol-specific effects from phase-specific 
effects, as any change in phase can only take place along with a change in sterol 
composition.  Additionally, two competing behaviors take place upon removal of 
sterol: FRET decreases as DHE is removed, but increases or decreases, depending on 
the phase behavior, as sterol is removed as reported in 9.3.2.  These two 
complications were removed by repeating the FRET study in the POPC-DPPC-Chol 
system.    
9.3.4  POPC-DPPC-Chol FRET Results 
 Use of the POPC-DPPC-Chol system allows for variation of phase while 
maintaining the sterol composition.  Figures 9.7 and 9.8 show the FRET behavior of 
POPC-DPPC-Chol membranes after addition of β-CD.  The sample containing 5% 
DPPC, residing in the ld phase undergoes an initial decrease in FRET followed by a 
plateau.  Equilibrium analysis reveals that k1 + k-1 is 0.018.  The sample containing 
50% DPPC (lo) shows a fairly constant FRET signal, with k1 + k-1 of 0.000. 
 These results verify that removal of cholesterol by β-CD most likely occurs 
primarily from the ld phase, with little, if any, cholesterol removed from the lo phase.       
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9.4  Discussion 
  The results of this study clearly show that the phase behavior of the 
membrane is of vital importance when interpreting results of cholesterol removal by 
β-CD.  Without exact knowledge of the membrane phase behavior, interpretation of 
results is difficult.  For example, several groups have found that β-CD removes 
cholesterol from DOPC-SM-Chol membranes at two different rates (1,6,7).  This 
complex behavior is most easily explained by simple phase behavior; at the 
temperature and compositions studied, the DOPC-SM-Chol system contains both lo 
and ld phases.  We found in our work that the rate of cholesterol extraction depends 
primarily on phase behavior of the membrane, with β-CD removing cholesterol 
primarily from the ld phase. 
  Additionally, we found that cholesterol removal by β-CD is an equilibrium 
reaction; β-CD removes cholesterol but also delivers it to the membrane.  This 
equilibrium behavior is often ignored in both natural and model membrane studies.  
When using β-CD to remove cholesterol from cells or model membranes, one must 
keep in mind that β-CD-Chol complexes are simultaneously delivering cholesterol to 
the membrane.  Likewise, when using β-CD-Chol complexes to deliver cholesterol to 
the membrane, one must remember that uncomplexed β-CD is simultaneously 
removing cholesterol from the membrane.     
9.5  Conclusions 
In the binary DMPC-Chol system, we demonstrated that complex behavior 
can be explained simply by phase behavior, thereby demonstrating that caution must 
be exercised when interpreting any β-CD extraction results.  Using membrane phase 
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behavior as a guide for our interpretation, we found that β-CD removes cholesterol 
preferentially from the ld phase over the lo phase.   
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Figure 9.1.  Spectral Shifts in DMPC-Chol Two-Phase Region After β-CD 
Addition.  Samples initially contained 10% ( ) or 20% ( ) cholesterol.    
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Figure 9.2.  Spectral Shifts in DMPC-Chol lo Region After β-CD Addition.  
Samples initially contained 40% ( ), 50% ( ),or 60% ( ) cholesterol.    
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Figure 9.3.  FRET in DMPC-Chol Two-Phase Region After β-CD Addition.  
Samples initially contained 10% ( ) or 20% ( ) cholesterol.     
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Figure 9.4.  FRET in DMPC-Chol lo Region After β-CD Addition. Samples 
initially contained 30% ( ), 35% ( ),or 40% ( ) cholesterol.   
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Figure 9.5.  FRET in DMPC-Chol ld Region After β-CD Addition  Equilibrium 
Analysis.  Samples initially contained 5% sterol (ld phase).   
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Figure 9.6.  FRET in DMPC-Chol lo Region After β-CD Addition  Equilibrium 
Analysis.  Samples initially contained 50% sterol (lo phase).   
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Figure 9.7.  FRET in POPC-DPPC-Chol ld Region After β-CD Addition  
Equilibrium Analysis.  Samples initially contained 30% sterol and 5% DPPC (ld 
phase).   
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Figure 9.8.  FRET in POPC-DPPC-Chol lo Region After β-CD Addition  
Equilibrium Analysis.  Samples initially contained 30% sterol and 50% DPPC (lo 
phase).   
 159
List of References 
 
 
 
 
1. Kilsdonk, E. P. C., P. G. Yancey, G. W. Stoudt, F. W. Bangerter, W. J. 
Johnson, M. C. Phillips, G. H. Rothblat. 1995. Cellular cholesterol efflux 
mediated by cyclodextrins. J. Biol. Chem. 270:17250-17256. 
 
2. Asgharian, B., D. A. Cadenhead, E. D. Goddard. 1988. The sequestering of 
surfactants from insoluble monolayers by a-, b- and g-cyclodextrins. Coll. 
Surf. 34:143-149. 
 
3. Ohtani, Y., T. Irie, K. Uekama, Z. Fukunaga, J. Pitha. 1989. Differential 
effects of a-, b- and g-cyclodextrins on human erythrocytes. Eur. J. Biochem. 
186:17-22. 
 
4. Ohvo, H., J. P. Slotte. 1996. Cyclodextrin-mediated removal of sterols from 
monolayers: Effects of sterol structure and phospholipids on desorption rate. 
Biochem. 35:8018-8024. 
 
5. Ohvo-Rekila, H., B. Ramstedt, P. Leppimaki, J. P. Slotte. 2002. Cholesterol 
interactions with phospholipids in membranes. Prog. Lip. Res. 41:66-97. 
 
6. Besenicar, M. P., A. Bavdek, A. Kadnik, P. Macek, G. Anderluh. 2008. 
Kinetics of cholesterol extraction from lipid membranes by methyl-b-
cyclodextrin - A surface plasmon resonance approach. Biochim. Biophys. 
Acta. 1778:175-184. 
 
7. Yancey, P. G., W. V. Rodrigueza, E. P. Kilsdonk, G. W. Stoudt, W. J. 
Johnson, M. C. Philips, G. H. Rothblat. 1996. Cellular cholesterol efflux 
mediated by cyclodextrins: demonstration of kinetic pools and mechanism of 
efflux. J. Biol. Chem. 271:16026-16034. 
 
8. Savitsky, A., J. E. Golay. 1964. Smoothing and differentiation of data by 
simplified least squares procedures. Anal. Chem. 36:1627-1639. 
 
9. Houston, P. L. 2001. Chemical kinetics and reaction dynamics, 1st ed. ed., 
McGraw-Hill, New York. 
 
 
 160
CHAPTER 10: ACTINOBACILLUS ACTINOMYCETEMCOMITANS TOXIN 
BINDING 
 
 
 
10.1 Introduction 
Lipid rafts are believed to be involved in disease processes as many pathogens 
use them to attack the host cell (1).  Many receptors tend to be concentrated in rafts, 
and therefore the raft becomes a location for toxin binding.  For example, pore 
forming toxins must bind to GPI-anchored proteins; rafts provide the necessary 
concentration of GPI-anchored proteins to allow for the oligimerization process that 
precedes membrane entry (2).  Some toxins are able to use rafts to take over cell-
signaling pathways to disrupt the immune response (3).  Additionally, there are 
several types of pathogens which display cholesterol-dependent binding behavior, in 
which case the raft becomes an entry site for the pathogen (4). 
A. actinomycetemcomitans is a gram-negative bacterium which is extremely 
pathogenic due to its multitude of virulence factors, including (among many others) a 
cytotoxin and a leukotoxin (Ltx) (5).  The cytotoxin produced by A. 
actinomycetencomitans is a cytolethal-distending toxin (Cdt) while the Ltx is a 
member of the repeats in toxin (RTX) family of toxins (5).   
  After a Cdt enters a cell, it causes the cell to become stuck in the G2 phase of 
the cell cycle, in which the cell grows and produces certain proteins to prepare for cell 
division.  Locked in this phase, the cell continues to expand without dividing, 
eventually disintegrating and dying (6).   
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The A. actinomycetencomitans Cdt is comprised of three subunits: CdtA, 
CdtB, and CdtC.  It is believed that the CdtB subunit is the active (A) unit and that a 
complex of the CdtA and CdtC subunits forms the binding (B) unit.  It has been 
observed that the CdtB subunit enters the cell, while the CdtA and CdtC subunits 
remain on the cell surface.  CdtB has been shown to induce cell cycle arrest without 
the other two subunits, but it is unable to enter the cell without them (7).  
Additionally, CdtB is more effective at inducing cell cycle arrest when CdtA and/or 
CdtC are present, which strongly indicates their role in binding (8).     
It has been shown that all three subunits of the A. actinomycetemcomitans Cdt 
are associated with ganglioside GM1, a glycosphingolipid which is known to be 
enriched in lipid rafts.  In addition, cells that have been treated with cyclodextrin (and 
are therefore cholesterol-depleted) are resistant to cell cycle arrest when exposed to 
the Cdt.  For these reasons, it has been hypothesized that the A. 
actinomycetemcomitans Cdt is dependent on the presence of rafts (9).  However, it 
remains unclear whether this dependence is actually due to the rafts or instead to the 
high cholesterol content of the membrane when rafts are present. 
The Ltx produced by A. actinomycetemcomitans is believed to interact with 
leukocyte function-associated antigen-1 (LFA-1) in a raft dependent manner.  Ltx has 
been shown to activate calpain, a protease which cleaves talin.  This severs the 
connection between LFA-1 and the cytoskeleton, causing clustering of LFA-1 on the 
surface as well as movement to raft regions.  It is believed that this movement of the 
LFA-1 along with the Ltx is vital for cytotoxicity, and it has been found that 
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treatment of cells with CD (depletion of cholesterol) reduces the cytotoxicity of Ltx 
(10).   
10.2  Experimental Overview 
The binding of A. actinomycetemcomitans Cdt and Ltx to model membranes 
containing cholesterol was studied.  Membranes contained DOPC and SM and 
varying amounts of cholesterol and were either raft-like or nonraft-like (11) in 
order to determine whether it is cholesterol or the presence of rafts which drives 
binding of these two toxins to cell membranes.     
10.2.1  Sample Preparation 
 Model membranes were created using the RSE technique.  Sample Set 10A 
was comprised of binary (DMPC-Chol) membranes.  These samples contained 
DMPC and 5 or 50% cholesterol, with the 5% cholesterol membrane being 
completely ld and the 50% cholesterol membrane being completely lo (12).  Sample 
Set 10B was comprised of ternary (DOPC-SM-Chol) membranes.  These samples 
contained DOPC, SM, and 10 or 25% cholesterol.  For each cholesterol composition, 
the SM composition was either 10 or 40%, so that the sample was either completely ld 
or was within the two-phase region (11).  A summary of sample compositions is 
provided in Table 10.1.   
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Table 10.1  Toxin Binding Sample Compositions 
Sample % Chol State (12)
10A-1 5% ld 
10A-2 50% lo 
Sample % Chol % SM State (11)
10B-1 10% 10% ld 
10B-2 10% 40% ld-lo 
10B-3 25% 10% ld 
10B-4 25% 40% ld-lo 
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Two sets of membranes were made with each of the above compositions.  One 
of these sets was labeled with DAN-PC, at a composition of 3 mol%, while the other 
set was unlabeled.   
 Purified toxin was added to DMPC-Chol membranes in a ratio of 4.4 ng toxin 
per mmol lipid and to DOPC-SM-Chol membranes in a ratio of 5.2 ng toxin per 
mmol lipid.  Samples were incubated at room temperature for 1 hour before emission 
scans were performed.   
 FRET efficiencies were calculated using the intensity of the donor (tryptophan 
in the toxin) emission maximum wavelength, 360 nm, in the presence and absence of 
acceptor (DAN-PC), as described in Chapter 4.  High energy transfer from Trp to 
DAN-PC indicates significant binding of toxin to the membrane, while low energy 
transfer indicates reduced binding.   
 Several toxin varieties were studied.  A wildtype Cdt was used as a control 
and compared with the Ltx as well as two mutants of the Cdt, in which the C-subunit 
had been disrupted (C-71 and C-74).     
10.2.2  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada) with a circulating 
water bath to maintain the sample temperature to + 0.5 oC.  The temperature was read 
on a cuvette thermometer (Fisher Corp., Philadelphia, PA). 
The samples were excited at 300 nm and the emission spectra were recorded 
from 325 to 550 nm.  All emission scans were conducted at 30oC.  The emission 
profiles were smoothed using a Savitsky and Golay protocol (13).     
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10.3  Results 
10.3.1  Cdt Binding to DMPC-Chol Membranes 
Figure 10.1 shows the binding (as determined by FRET efficiency) of 
wildtype Cdt as well as the mutants, C-71 and C-74 to DMPC-Chol membranes.  
Wildtype toxin binds preferentially to membranes containing more cholesterol in this 
binary DMPC-Chol system.  Both mutant toxins display similar behavior, binding 
preferentially to the membranes containing more cholesterol.  For each toxin type, 
binding is 2 to 3 times higher in the 50% cholesterol sample than in the 5% 
cholesterol sample.     
In addition, it is observed that the binding of the mutants to nonraft 
membranes is similar to binding of the wildtype in nonraft membranes.  Likewise, 
binding of the mutants to raft membranes is similar to binding of the wildtype to raft 
membranes.  These results suggest that the C-subunit has little effect on toxin binding 
in DMPC-chol membranes.   
10.3.2  Cdt Binding to DOPC-SM-Chol Membranes 
Figures 10.2, and 10.3 show the binding results in DOPC-SM-Chol 
membranes containing 10% cholesterol and 25% cholesterol, respectively.   
In the membranes containing 10% cholesterol (Figure 10.2), the wildtype 
toxin shows a slight binding preference for the raft-like membrane over the nonraft-
like membrane.  The mutant toxins display a similar behavior  slight preference for 
raft-like membranes over nonraft-like membranes.  In both raft-like and nonraft-like 
membranes containing 10% cholesterol, binding of both mutants is less than binding 
of the wildtype.     
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Binding of the toxin and mutants to DOPC-SM-Chol membranes containing 
25% cholesterol (Figure 10.3) is slightly preferential to raft-like membranes.  In these 
membranes, binding of both mutants is less than binding of the wildtype to both raft 
and nonraft membranes.   
 The overall wildtype binding appears to be independent of the cholesterol 
composition of the membrane, and more dependent on whether the membrane is raft-
like or nonraft-like.  Binding of the wildtype in nonraft-like membranes is about the 
same, regardless of cholesterol composition.  Likewise, wildtype binding in raft-like 
membranes is about the same regardless of the cholesterol content of the membrane.     
In all ternary membranes, binding of the mutants is less than binding of the 
wildtype, indicating that disruption of the C-subunit does impact the binding ability 
of the toxin.   
10.3.3  Ltx Binding to DOPC-SM-Chol Membranes 
Figure 10.4 shows Ltx binding in DOPC-SM-Chol membranes (25% 
cholesterol).  In both raft and nonraft membranes, binding is extremely low, 
indicating that Ltx is unable to bind directly to either type of model membrane.       
10.4  Discussion 
It appears that the binding of A. actinomycetemcomitans Cdt depends on the 
presence of rafts.  In the DMPC-Chol system, the Cdt showed preferential binding in 
the raft-like membrane.  This could be due to either the raft-like nature of the 
membrane or the higher cholesterol composition of the 50% cholesterol membrane.  
Results from the ternary system clarify this result.  In the DOPC-SM-Chol system, 
the Cdt also shows preferential binding for the raft-like membrane, regardless of the 
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cholesterol composition of the membrane.  These results together indicate that the Cdt 
binds preferentially to raft-like membranes over nonraft-like membranes. 
It has been demonstrated that A. actinomycetemcomitans Cdt binds 
preferentially to rafts in natural cells (14).  However, the actual mechanism 
responsible for binding has not been elucidated.  It is possible that this preferential 
binding observed in natural cells is due to the concentration of receptors in raft-like 
areas (14).  Here, we found that in model membranes without receptors, binding still 
appears to be raft-dependent.  These results suggest that the C-subunit contains a 
cholesterol recognition consensus (CRAC) site, which has been observed in other 
proteins (15,16), which could be responsible for the type of behavior observed here.   
Additionally, Ltx showed limited binding in the model system.  This behavior 
highlights the difference between a protein containing a putative CRAC and one that 
does not.  Ltx is known to associate with LFA-1, which is not present in these model 
membranes.  The lack of Ltx binding contrasts with the Cdt, which binds without any 
membrane receptors.             
In addition, the C-subunit appears to be responsible for this raft-dependent Cdt 
binding in model membranes, as disruption of the C-subunit limits binding of the 
toxin in the DOPC-SM-Chol membranes.  The putative CRAC site is most likely 
present on this C-subunit.   
10.5  Conclusions 
A. actinomycetemcomitans Cdt binds preferentially to raft-like over nonraft-
like membranes.  Additionally, it contains a putative CRAC site on the C subunit, 
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which allows it to bind to model membranes which do not have binding factors.  Ltx 
does not have this CRAC site and is unable to bind to model membranes.    
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Figure 10.1.  Cdt Binding to DMPC-Chol Membranes.  Wildtype and mutant Cdt 
(C-71 and C-74) binding (as measured by FRET) to DMPC-chol membranes is 
shown. 
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Figure 10.2.  Cdt Binding to DOPC-SM-Chol (10% Chol) Membranes.  Wildtype 
and mutant Cdt (C-71 and C-74) binding (as measured by FRET) to DOPC-SM-chol 
membranes containing 10% cholesterol is shown. 
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Figure 10.3.  Cdt Binding to DOPC-SM-Chol (25% Chol) Membranes.  Wildtype 
and mutant Cdt (C-71 and C-74) binding (as measured by FRET) to DOPC-SM-chol 
membranes containing 25% cholesterol is shown. 
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Figure 10.4.  Ltx Binding to DOPC-SM-Chol (25% Chol) Membranes. 
 
 
 173
List of References 
 
 
 
 
1.   Simons, K., R. Ehehalt. 2002. Cholesterol, lipid rafts, and disease. J. Clin. 
Invest. 110:597-603. 
 
2. Abrami, L., F. G. van der Goot. 1999. Plasma membrane microdomains act as 
concentration platforms to facilitate intoxication by aerolysin. J. Cell Biol. 
147:175-184. 
 
3. Manes, S., G. del Real, C. Martinez-A. 2003. Pathogens: Raft hijackers. 
Nature Rev. Immunol. 3:557-568. 
 
4. van der Goot, F. G., T. Harder. 2001. Raft membrane domains: from a liquid-
ordered membrane phase to a site of pathogen attack. Sem. Immunol. 13:89-
97. 
 
5. Fives-Taylor, P. M., D. H. Meyer, K. P. Mintz, C. Brissette. 2001. Virulence 
factors of Actinobacillus actinomycetemcomitans. Periodontol. 20:136-167. 
 
6. Pickett, C. L., C. A. Whitehouse. 1999. The cytolethal distending toxin 
family. Trends Microbiol. 7:292-297. 
 
7. Ceelen, L. M., A. Decostere, R. Ducatelle, F. Haesebrouck. 2006. Cytolethal 
distending toxin generates cell death by inducing a bottleneck in the cell 
cycle. Microbiol. Res. 161:109-120. 
 
8. Shenker, B. J., D. Besack, T. McKay, L. Pankoski, A. Zekavat, D. R. Demuth. 
2004. Actinobacillus actinomycetemcomitans cytolethal distending toxin 
(Cdt): Evidence that the holotoxin is composed of three subunits: CdtA, CdtB, 
and CdtC. J. Immunol. 172:410-417. 
 
9. Boesze-Battaglia, K., D. Besack, T. McKay, A. Zekavat, L. Otis, K. Jordan-
Sciutto, B. J. Shenker. 2006. Cholesterol-rich membrane microdomains 
mediate cell cycle arrest induced by Actinobacillus actinomycetemcomitans 
cytolethal-distending toxin. Cell. Microbiol. 8:823-836. 
 
10. Fong, K. P., C. M. F. Pacheco, L. L. Otis, S. Baranwal, I. R. Krieba, G. 
Harrison, E. V. Hersh, K. Boesze-Battaglia, E. T. Lally. 2006. Actinobacillus 
actinomycetemcomitans leukotoxin requires lipid microdomains for target cell 
toxicity  Cell. Microbiol. 8:1953-1767. 
 
11. Veatch, S. L., S. L. Keller. 2005 Seeing spots: Complex phase behavior in 
simple systems. Biochim. Biophys. Acta 1746:172-185. 
 174
 
12. Tampe, R., A. von Lukas, H. J. Galla. 1991. Glycophorin-induced cholesterol-
phospholipid domains in dimyristoylphosphatidylcholine bilayer vesicles. 
Biochem. 30:4909-4916. 
 
13. Savitsky, A., J. E. Golay. 1964. Smoothing and differentiation of data by 
simplified least squares procedures. Anal. Chem. 36:1627-1639. 
 
14. Boesze-Battaglia, K., D. Besack, T. McKay, A. Zekavat, L. Otis, K. Jordan-
Sciutto, B. J. Shenker. 2006. Cholesterol-rich membrane microdomains 
mediate cell cycle arrest induced by Actinobacillus actinomycetemcomitans 
cytolethal-distending toxin. Cell. Microbiol.  8:823-836. 
 
15. Li, H., V. Papadopoulos. 1998. Peripheral-type benzodiazepine receptor 
function in cholesterol transport. Identification of a putative cholesterol 
recognition/interaction amino acid sequence and consensus pattern. 
Endocrinol. 139:4991-4997. 
 
16. Li, H., Z. Yao, B. Degenhardt, G. Teper, V. Papadopoulos. 2001. Cholesterol 
binding at the cholesterol recognition/ interaction amino acid consensus 
(CRAC) of the peripheral-type benzodiazepine receptor and inhibition of 
steroidogenesis by an HIV TAT-CRAC peptide. Proc. Natl. Acad. Sci. USA. 
98:1267-1272. 
 
 
 175
CHAPTER 11: CONCLUSIONS AND RECOMMENDATIONS 
 
 
 
In this work, we developed a steady-state fluorescence assay to detect and 
measure domain size in model membranes and used it to investigate factors affecting 
domain size and to determine the kinetics of domain formation.  In addition, we 
investigated the direct binding of A. actinomycetemcomitans to lipid rafts.  Here, we 
present the conclusions and recommendations for future work from each of these 
studies.     
11.1  Fluorescence Assay to Detect and Measure Domain Size 
11.1.1  Conclusions 
Of the four FRET pairs studied, the DAN-PC and DHE pair was found to 
display the required differential partitioning between the two phases.  DAN-PC was 
determined, by the DAN-PC spectral shift, to partition almost exclusively in the ld 
phase, while FRET indicated that DHE partitions predominately in the lo phase.  Use 
of this FRET pair to determine domain size is limited to ternary systems containing a 
saturated phospholipid, an unsaturated phospholipid, and cholesterol, where it is less 
perturbing than in systems containing only one or more saturated phospholipids and 
cholesterol.   
11.1.2  Recommendations 
We observed during this work that the Förster distance of DHE and DAN-PC, 
a number which is generally considered a constant, varied depending on the 
composition of the membrane.  For the purposes of this work, it was assumed that the 
Förster distance varied with cholesterol composition, but not phospholipid 
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composition, and the no domains FRET profile (along the binary low-Tm 
phospholipid and cholesterol edge of the phase diagram) at each cholesterol 
composition was used to determine the Förster distance.  Ideally, the Förster distance 
would be known exactly.  This could be done by determining it experimentally at 
each composition; however, this would be extremely time-consuming.  Another 
solution would be to modify the model to describe domain size as a function of 
Förster distance.  This solution allows for comparison of domain size as a function of 
composition using a single-parameter fit. 
 Identification of another FRET pair which displays differential partitioning 
and a greater spectral overlap could be beneficial for several reasons.  It would be 
useful to compare results using different FRET pairs to ensure that results are 
accurate and not unique to the DAN-PC/DHE FRET pair.  In addition, identification 
of a FRET pair with a higher spectral overlap would allow smaller probe 
compositions to be used which would minimize probe-specific effects.         
11.2  Demarcation of the lo Transition in Model Membranes 
11.2.1  Conclusions 
A distinct lo transition was observed in all of the ternary systems studied.  This 
transition is present, regardless of the presence of a two-phase region.  The 
compositions at which this transition occurs depends entirely on the Tm of the lipid 
components, with higher-Tm phospholipids having a lo transition at lower cholesterol 
compositions and lower-Tm phospholipids having a lo transition at higher cholesterol 
compositions.  At higher temperatures, the lo transition shifts to higher cholesterol 
compositions.       
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11.2.2  Recommendations 
The lo transition has been thoroughly mapped in the five ternary systems 
studied in this work.  Determination of the lo transition in a DLPC-DSPC-Chol 
system could be useful for a more complete understanding of the effect of saturation 
of the low-Tm lipid on the transition.  In addition, characterization of systems 
containing 1,2-diarachidoyl-sn-glycero-3-phosphocholine (20:0) would allow for a 
more thorough interpretation of the effect of chain length of the high-Tm lipid on the 
lo transition.   
11.3  Determination of Domain Sizes in Model Membranes 
11.3.1  Conclusions 
Nanoscale domains were found in four of the systems studied: DOPC-DPPC-
Chol, DLPC-DPPC-Chol, DOPC-DSPC-Chol, and POPC-DSPC-Chol.  Only the 
POPC-DPPC-Chol system did not contain domains.  Distribution of domain sizes in 
the POPC-DSPC-Chol system was slightly different than in the DOPC-DPPC-Chol 
and DOPC-DSPC-Chol systems, while the distributions of domain sizes between the 
two DOPC-containing systems were very similar.     
Domain size was found to be most influenced by variation in line tension.  
Phospholipid chain length and chain saturation both play a role, due to their impact 
on line tension, but the two effects are difficult to separate.   
11.3.2  Recommendations 
Characterization of several additional ternary systems would be useful for a 
more thorough evaluation of the effect of saturation of the low-Tm lipid and length of 
the high-Tm lipid.  For this purpose, a DLPC-DSPC-Chol system could be studied to 
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compare to the DOPC-DSPC-Chol and POPC-DSPC-Chol systems.  In addition, 
replacement of DSPC with diarachidoylphosphocholine would allow comparison with 
a longer-chain high-Tm lipid.   
11.4  Kinetics of Domain Formation 
11.4.1  Conclusions 
We found that composition-driven domain growth occurs on the time-scale of 
hours, while domain dissipation occurs on the order of minutes.   
11.4.2  Recommendations 
The major complication in the domain formation and dissipation studies was 
the variation of composition with time.  In other words, the FRET signal changed due 
to domain growth but also probe partitioning changes.  In order to avoid this 
complication, temperature studies could be performed at a single composition.  
Comparison of temperature-dependent growth (or dissipation) rates at several 
compositions would allow for determination of composition effects on growth rates. 
In addition, domain dissipation was found to occur so quickly after mixing 
that the FRET signal had already changed by the time the initial sample reading was 
obtained.  This complication is due to the nature of steady-state emission scanning; 
identification of a technique with a faster response time could eliminate this problem.   
11.5  Kinetics of Cholesterol Removal 
11.5.1  Conclusions 
We showed that β-CD removal of cholesterol is dependent on membrane 
phase behavior, and interpretation can only proceed by taking phase behavior into 
account.  Specifically, we found that β-CD removes cholesterol from the ld phase 
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preferentially over the lo phase, a discovery which has significant implications in 
natural cell studies.   
11.5.2  Recommendations 
 Analysis of the kinetic data required an assumption that the complexation 
reaction rate was first-order with respect to cholesterol and zero-order with respect to 
cyclodextrin.  Additional studies could verify this assumption by systematically 
varying the cholesterol composition and cyclodextrin concentration.     
11.6  A. actinomycetemcomitans Binding 
11.6.1  Conclusions 
Evidence that A. actinomycetemcomitans Cdt binds directly (without 
receptors) to raft-like membranes was discovered; this suggests that Cdt contains a 
CRAC site on the C subunit, which allows it to bind directly to membranes 
containing cholesterol.  A second virulence factor of A. actinomycetemcomitans, Ltx, 
did not display this direct binding behavior.   
11.6.2  Recommendations 
In order to separate raft-dependent behavior from cholesterol-dependent 
behavior, Cdt binding experiments could be performed in a non-raft containing 
system, such as POPC-DPPC-Chol.   
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APPENDIX A: EFFECT OF ESTROGEN ON RAFTS: IMPLICATIONS FOR 
GALLSTONE PATHOGENESIS 
 
 
 
 
A.1.  Introduction 
Formation of gallstones occurs via a multi-step process.  Unilamellar vesicles 
composed of cholesterol and phospholipids are micellized by bile salts.  Depending 
on the ratio of bile salts to cholesterol, this process results in an equilibrium bile 
solution containing either micelles alone or both micelles and small unilamellar 
vesicles (SUVs).  Because phospholipids are more easily micellized than cholesterol, 
any remaining vesicles at equilibrium are enriched in cholesterol (1).  It has been 
demonstrated that aggregation of these SUVs into MLVs directly precedes cholesterol 
crystallization (1,2). 
 Supersaturation of biliary cholesterol is a necessary, but not sufficient, factor 
in gallstone pathogenesis.  Additional nucleation factors are required, in the form of 
pro-nucleating factors in some individuals, anti-nucleating factors in others, or some 
combination of the two (3).  Proposed pro-nucleating factors include mucous 
glycoproteins, calcium, and bilirubin, and certain apolipoproteins have been proposed 
as anti-nucleating factors (1,4).   
 Estrogen has been suggested as a potential pro-nucleating agent for several 
reasons.  First, women are twice as likely as men to develop gallstones (5).  In 
addition, men who have been treated with estrogen during prostate cancer therapy are 
more likely to develop gallstones than patients treated by other methods (6).  
Gallbladder function is affected by female steroids, as evidenced by an increase in 
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volume and a decrease in motility during pregnancy or with the use of contraceptive 
steroids (7).  Both the increase gallbladder volume and decrease in motility are linked 
to a higher incidence of gallstone pathogenesis.  
 In this work, we attempted to determine if there is a difference in cholesterol 
nucleation between males and females and if so, if estrogen is a contributory factor 
responsible for these differences.  Specifically, we are interested in determining 
whether estrogen interacts with lipid rafts during the nucleation process.   
A.2.  Experimental Overview 
A.2.1.  Materials  
In addition to the chemicals reported in Chapter 4, the following were used in 
this study.  β-estradiol, bovine serum albumin (BSA), and β-estradiol-6-(O-
carboxymethyl)oxime:BSA were purchased from Sigma Chemical Co. (St. Louis, 
MO).  All chemicals were used without further purification.   
β-estradiol is a steroid, composed of a four-ringed structure, much like 
cholesterol.  In contrast to cholesterol, however, β-estradiol contains two hydroxyl 
groups, one at either end of the molecule.  The chemical structure of β-estradiol is 
shown in Figure A.1.   
A.2.2.  Native Prairie Dog Bile Harvesting and Labeling 
Films of DHE and/or DAN-PC were prepared using the film deposition 
technique. DHE (0.3 mg) and DAN-PC (0.45 mg) dissolved in chloroform were 
added to scintillation vials.  The chloroform was evaporated under a stream of 
nitrogen and any residual chloroform was removed by exposing the samples to a 
vacuum overnight.  Films were stored at -20oC until they were used.     
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Prairie dog gallbladder bile was harvested via cholecystectomy from both 
male and female prairie dogs fed normal chow.  Bile samples were diluted 6 times 
with buffer containing 0.15 M NaCl, 5 mM CaCl2, 5 mM HEPES, and 3 mM NaN3 at 
a pH of 7.4.  Two mL of the diluted bile was added to the DHE-DAN-PC films on 
day 0, and the samples were vortex-mixed to incorporate the fluorescent probes and 
then incubated for one hour before use.   
A.2.3.  Model Bile Preparation 
Model bile solutions were prepared using the RSE technique (8).  Stock 
solutions of DMPC, cholesterol, DHE, DAN-PC, and estradiol dissolved in 
chloroform were added to 20 mL flat bottom vials in the required amounts.  3 mL of 
heated aqueous buffer was added.  The solution was then vortex mixed while exposed 
to a vacuum (4.92 inches mercury absolute pressure) for one minute and then diluted 
with buffer to a final lipid concentration of 1 mM.  The buffer (pH of 7.4) contained 
0.15 M NaCl, 5 mM CaCl2, 5 mM HEPES, and 3 mM NaN3. 
Three modes of estrogen delivery were used in this work: protein transport, 
vesicle transport, and vesicle direct incorporation.   
Protein transport samples were created with 20% sterol and DMPC (Sample 
Set AA); these vesicles were labeled with DHE (5%) and DAN-PC (ALR of 0.00 to 
0.12).  To these vesicles was added either BSA (6.6 mg) or a combination of 
unlabeled BSA (2.2 mg) and BSA labeled with estradiol (4.4 mg).     
Vesicle transport samples contained two vesicle sets.  The first set (Sample 
Set AB-1) contained 20% sterol, DMPC, 5% DHE, and DAN-PC (ALR of 0.00 to 
0.12).  The second set (Sample Set AB-2) contained DMPC and estradiol at a 
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composition of 0% to 60%.  These two vesicle solutions were well mixed and 
incubated for one hour.       
The direct incorporation vesicles (Sample Set AC) were made with varying 
cholesterol compositions.  Samples were made containing 5%, 20%, or 50% sterol to 
correspond to the ld phase, the two-phase (ld and lo) region, or the lo phase according 
to the phase diagram for the DMPC-Cholesterol system at 30oC (9).  Each of these 
samples also contained 5% DHE, 0 to 12% DAN-PC, and 0 to 10% estrogen.   
Spectral shift samples (Sample Set AD) containing DMPC, estrogen (0  
55%), and DAN-PC at an ALR of 0.03 were created.   
Model bile sample compositions are shown in Table A1. 
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Table A1.  Model Bile Sample Compositions 
Sample ID % cholesterol % β-estradiol 
AA 20% 0% 
AB-1 20% 0% 
AB-2 0% 0  60% 
AC-1 5% 0  0% 
AC-2 20% 0  10% 
AC-3 50% 0  10% 
AD-1 0% 0  55% 
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A.2.3.  Fluorescence Measurements 
Fluorescence measurements were obtained using a steady-state fluorescence 
spectrometer (Photon Technology International, Ontario, Canada, model Q-5/W-601) 
with a circulating water bath to maintain the sample temperature to +0.5oC.  The 
temperature was read on a cuvette thermometer (Fisher Corp., Philadelphia, PA, 
model 15-078J). 
Samples were excited at 300 nm and the emission spectra were recorded from 
325 to 550 nm.  Native bile emission scans were conducted at room temperatures, and 
model bile emission scans were conducted at 30oC.  The emission profiles were 
smoothed using a Savitsky and Golay protocol (10).     
A.2.4.  FRET Measurements 
In this work, two methods of FRET measurement were used: the ratio of 
donor to acceptor peaks and the efficiency of energy transfer.   
To study cholesterol nucleation, the ratio of donor and acceptor peaks (R) is 
measured.   
A
D
F
FR =  
 Where FD is the intensity of the donor at is maximal wavelength (373 nm for 
DHE) and FA is the intensity of the acceptor at its maximal wavelength (515 nm for 
DAN-PC).  During cholesterol crystallization, DHE leaves the membrane with 
cholesterol, while DAN-PC remains in the membrane.  This increased distance 
between the probes causes FRET to decrease, which is observed by an increase in 
donor peak and a decrease in acceptor peak, leading to an increased ratio (11).     
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Measurement of domain size is accomplished through the use of FRET 
efficiency, as defined previously (Chapter 4).  This experimental efficiency is related 
to domain size, as the acceptor is excluded from the domains and DHE partitions 
preferentially into the domains.  An increase in domain size therefore leads to a 
decrease in FRET.    
A.3.  Results 
A.3.1.  Native Bile Results 
The FRET ratio for six pairs of female and male prairie dog bile samples, 
labeled with DHE and DAN-PC were measured over a two-month period.  Results are 
shown in Figure A2.  Regardless of gender, a steep initial increase is observed, 
followed by a plateau region.   
In five of the six pairs, the ratio in the female sample is higher than in the 
male sample.  This result suggested that both types of samples begin to crystallize 
almost immediately, as observed by the steep initial increase in R.  The female 
samples however, appear to crystallize to a greater extent than the male samples on 
average.   
The initial nucleation event may be caused by several factors in the 
experimental setup.  Removal of the bile from the gallbladder decreases the motility 
and may initiate crystallization.  Alternatively, labeling of the samples with DHE may 
increase the sterol content of the bile microstructures and cause 
nucleation/crystallization.  Regardless of which of these mechanisms is responsible 
for the initiation of nucleation/crystallization, it appears that crystallization occurs to 
a greater extent in female bile than in male bile. 
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The average behavior is shown in Figure A3.  Figure A3A shows the overall 
summary of the first three sets of data and Figure A3B shows the overall summary of 
the second three sets of data.  In both cases, the average female ratio is slightly higher 
than the male; however, statistical analysis of these samples sets indicates that this 
difference is statistically irrelevant (p > 0.5).      
A.3.2.  Model Bile Results 
 In order to determine if estrogen is involved in the difference in cholesterol 
crystallization in bile between males and females, we investigated the effect of 
estrogen on raft size in model bile.  The first step involved identification of a feasible 
method of estrogen delivery.  Three possible delivery methods were used in this 
initial study: protein transport, vesicle transport, and vesicle direct incorporation.   
  In the protein transport study, DMPC-Chol vesicles, containing 20% sterol 
and labeled with DHE and DAN-PC, were mixed with BSA and/or BSA-estradiol.  
Results of this study are shown in Figure A4.  The FRET profile increases very 
slightly when estradiol-labeled BSA is added, compared to addition of plain BSA.  
The increase in FRET profile is very small even with the addition of a large amount 
of labeled protein, however, so a different method of transport was attempted.   
 For the vesicle transport study, a set of DMPC-Chol vesicles was labeled with 
DHE and DAN-PC and mixed with a set of DMPC vesicles containing 0 to 60% 
estradiol.  As see in Figure A5, the FRET profile increases slightly with addition of 
estradiol, as in the protein transport studies, but again, the change is very small 
relative to the composition of estradiol used.       
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 Only very small changes in FRET were observed in these two transport 
studies, even with addition of extremely large estradiol compositons.  For this reason, 
a less biologically relevant option, vesicle direct incorporation, was used.  This 
method eliminates the transport limitations of the protein transport and vesicle 
transport techniques.     
 For the vesicle direct incorporation studies, DMPC-Chol vesicles containing 
various amounts of estrogen and labeled with DAN-PC and DHE were created.  Each 
of these sample sets represented a different type of phase behavior: completely ld (5% 
cholesterol), ld and lo (20% cholesterol), and completely lo (50% cholesterol).  
 Results of this study are shown in Figure A6.  In ld samples, addition of 
estrogen causes the FRET profile to increase slightly, as seen in Figure A6A.  
Samples that are within the two-phase region, display a decrease in FRET profile with 
increasing estrogen composition (Figure A6B).  In the lo region, FRET profiles 
increase significantly with estrogen composition (Figure A6C).         
 The increase in FRET profile with addition of estrogen in the samples that are 
100% ld or lo (Figures A6A and A6C, respectively) could be due to a slight induction 
of order by estrogen, which causes the DAN-PC and DHE to move slightly closer on 
average, resulting in an increase in energy transfer.  However, it must be noted that 
while estrogen may cause the membrane to condense slightly, it does not appear to 
induce the formation of a lo phase by itself at the temperature and compositions used 
in this study.  A DAN-PC spectral shift study, shown in Figure A7, shows a constant 
emission max for all estrogen compositions in DMPC-estrogen membranes at 30oC.  
This is in stark contrast to the results in which the sterol used was cholesterol 
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(Chapter 5) in which the DAN-PC blue shift indicates the formation of a lo phase.  
When cholesterol is replaced with estrogen, no blue shift is observed, and therefore, it 
can be said that estrogen does not cause the lo phase to form.    
 The decrease in FRET that is observed when the sample is within the two-
phase region (Figure A6B) is most likely due to one of two things: 1) an increase in 
domain radius or 2) initiation of cholesterol nucleation.  Differentiation of these two 
possibilities is not possible with the current data; however, it can be concluded that 
estrogen disrupts lipid rafts.     
A.4.  Discussion 
 The native bile results suggest that in general, cholesterol crystallization in 
female bile occurs to a greater extent than in male bile.  Although differences in the 
average behavior between males and females is not statistically relevant, it is 
interesting that in five of the six bile pairs, the female bile exhibits greater cholesterol 
crystallization than does the male bile.      
 In addition, we found that estrogen disrupts lipid rafts, while having only a 
limited effect on membranes that do not contain rafts.  The exact nature of this effect 
has not been elucidated, but one possibility is that estrogen increases the order of the 
membrane.  Within the raft, which is already highly ordered, this may cause the 
cholesterol to nucleate.   
A.5.  Conclusions 
In this work, we have shown that there is a potential difference in the 
nucleation of male and female bile, although additional samples are required in order 
to verify this result.  In addition, we found that β-estradiol clearly disrupts lipid rafts, 
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and that this may be a mechanism by which estrogen influences cholesterol 
nucleation in bile.   
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Figure A1.  Chemical Structure of β-estradiol.   
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Figure A2.  Cholesterol Crystallization From Native Bile.  The FRET ratio (R) for 
6 pairs of male ( ) and female ( ) prairie dog bile, fluorescently labeled with DHE 
and DAN-PC is shown.     
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Figure A3.  Cholesterol Crystallization From Native Bile  Averages.  Overall 
summary of FRET ratio in fluorescently labeled male ( ) and female ( ) prairie dog 
bile samples is shown.  In the first three sets (Figure A3A), readings were obtained on 
Days 0, 14, 28, and 56.  In the second three sets (Figure A3B), readings were 
obtained every 7 days.   
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Figure A4.  Protein Delivery of β-estradiol to Model Bile.  FRET profiles of 
DMPC-Chol vesicles, containing 20% sterol (within the ld-lo coexistence region) are 
shown after addition of BSA ( ) or BSA and BSA-estradiol ( ).  
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Figure A5.  Vesicle Delivery of β-estradiol to Model Bile.  FRET profiles of 
DMPC-Chol vesicles, containing 20% sterol (within the ld-lo coexistence region) after 
addition of DMPC vesicles containing 0% estradiol ( )  20% estradiol ( ), and 40% 
estradiol ( ) are shown.    
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Figure A6.  Direct Incorporation of β-estradiol to Model Bile.  FRET efficiency 
profiles of model bile samples containing DMPC, estrogen, and 5% cholesterol 
(A6A), 20% cholesterol (A6B), and 50% cholesterol (A6C).  Samples contained 0% 
( ), 2.5% ( ), 5% ( ), 7.5% ( ), or 10% ( ) estradiol.     
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Figure A7.  DAN-PC Spectral Shifts in DMPC-estradiol Membranes.  DAN-PC 
emission maxima are plotted as a function of estrogen composition in DMPC-
estrogen membranes at 30oC.     
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ALR:  acceptor-to-lipid ratio 
AFM:  atomic force microscopy 
BSA:  bovine serum albumin 
CaCl2:  calcium choride 
CD:  β-cyclodextrin 
Cdt:  cytolethal distending toxin 
Chol:  cholesterol 
DAN-DHPE:  N-(5-dimethylaminonaphthalene-1-sulfonyl)-1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine 
DAN-PC:  1-myristoyl-2-[12-[(5-dimethylamino-1-
naphthalenesulfonyl)amino]dodecanoyl]-sn-glycero-3-phosphocholine 
DANSYL:  5-(dimethylamino)naphthalene-1-sulfonyl 
DHE:  dehydroergosterol 
DLPC:  1,2-dilauroyl-sn-glycero-3-phosphocholine 
DMPC:  1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DOPC:  1,2-dioleoyl-sn-glycero-3-phosphocholine 
DPH:  diphenylhexatriene 
β-DPH-HPC:  2-(3-diphenylhexatrienyl)propanoyl)-1-hexadecanoyl-sn-glycero-3-
phosphocholine 
DPPC:  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DRM:  detergent resistant membrane 
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DSPC:  1,2-distearoyl-sn-glycero-3-phosphocholine 
FRET:  Forster resonance energy transfer 
GalCer:  galactosylceramide 
GM1:  monosialotetrahexosylganglioside 
GPI:  glycophosphatidylinositol 
HEPES:  4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
ld:  liquid-disordered 
LFA-1:  leukocyte function-associated antigen-1 
Ltx:  leukotoxin 
lo:  liquid-ordered 
MLV:  multilamellar vesicle 
NaCl:  sodium chloride 
NaN3:  sodium azide 
NMR:  nuclear magnetic resonance 
PC:  phosphatidylcholine 
POPC:  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
RSE:  rapid solvent exchange 
SM:  sphingomyelin 
so:  solid-ordered 
SPT:  single particle tracking 
SUV:  small unilamellar vesicle 
Tm:  Transition temperature 
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TMA-DPH:  1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p 
toluenesulfonate 
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